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ABSTRACT OF THE DISSERTATION 
Refining Associations between Targeted Genes and the  
Development of Substance Use Disorders 
by 
Emily Olfson 
Doctor of Philosophy in Biology and Biomedical Sciences 
Human and Statistical Genetics 
Washington University in St. Louis, 2016 
Professor Laura J. Bierut, Chair 
Recent genome-wide association studies (GWAS) provide strong evidence for the contribution 
of a few specific genes to alcohol and nicotine dependence. Chapter 2 explores numerous 
previously identified candidate genes for alcohol dependence using a publically available 
GWAS. I found that many candidate loci do not replicate, highlighting the utility of GWAS for 
focusing on disease associated genes. Chapters 3-5 dissect associations between three genome-
wide significant genes and substance use disorders. Chapter 3 focuses on a functional variant in 
alcohol dehydrogenase (ADH) 1B.  Through examining 1,550 adolescent drinkers in the 
Collaborative Study on the Genetics of Alcoholism (COGA), I extended adult findings by 
showing that this ADH1B variant protected against early drinking milestones. Furthermore, I 
provided evidence for a gene-by-environment interaction where best friends drinking eliminated 
this genetic protective effect, illustrating the important interplay between genetic and 
environmental factors in the development of drinking behaviors. Chapter 4 examines variation in 
the nicotine metabolizing cytochrome P450 gene CYP2A6. Previous studies show slow 
metabolizers smoke fewer cigarettes, but provide conflicting results on the role of CYP2A6 in 
x 
nicotine dependence. Using a COGA young adult sample, I found that CYP2A6 metabolism was 
not associated with smoking initiation or daily smoking, but among daily smokers, slow 
metabolism was associated with increased risk of dependence. This association was replicated in 
an independent sample from the Collaborative Study of Nicotine Dependence, adding insight 
into the complex role of CYP2A6 across stages of smoking behaviors. Chapter 5 focuses on 
coding variation in the α5 nicotinic receptor subunit gene (CHRNA5), which harbors a 
nonsynonymous common variant robustly associated with nicotine dependence. I examined 
targeted sequence data of CHRNA5 from approximately 3,000 nicotine dependent cases and 
controls, with independent replication of common and low frequency variants in 12 studies. I 
found that common, low frequency, and rare CHRNA5 coding variants were independently 
associated with increased nicotine dependence risk. Incorporating coding variants beyond the 
well-studied common variant increased the variance in nicotine dependence explained by 
CHRNA5. Overall, this dissertation advances our understanding of targeted genes for substance 
use disorders by incorporating important environments, critical developmental periods, and rare 
variants. 
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“The ideal art, the noblest of art: working with the complexities of life, refusing to simplify, to 
‘overcome’ doubt.” 
 
-Joyce Carol Oates 
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CHAPTER ONE: 
Introduction: Substance use disorders are complex diseases  
with important public health implications  
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1.1 THE PUBLIC HEALTH BURDEN OF SUBSTANCE USE DISORDERS 
Substance use disorders are a leading cause of preventable death in both the United States 
and worldwide. Each year, 3.3 million people die due to the harmful effects of alcohol, 
representing 5.9% of all deaths across the world (WHO, 2014b). From 2006-2010, 
approximately 88,000 deaths and 2.5 million years of potential life were lost in the United States 
due to alcohol consumption (Stahre et al., 2014). Heavy drinking can have immediate health 
related effects through injuries, violence, alcohol poisoning, and risky sexual behaviors. Over 
time, excessive alcohol use can lead to several chronic diseases, including heart disease, liver 
disease, cancer, and mental health problems. Tobacco smoking similarly causes many chronic 
diseases, including heart disease, lung cancer, and respiratory illnesses. Nearly 6 million people 
die each year from tobacco products worldwide (WHO, 2014a). In the United States alone, 
cigarette smoking causes about one of every five deaths each year, accounting for approximately 
480,000 deaths annually (CDC, 2014). Beyond excessive morbidity and mortality associated 
with these behaviors, economically society pays a high price for substance use. Approximately 
11% of the total federal and state government budget is spent on the consequences of alcohol, 
tobacco, and other drug use (CASAColumbia, 2009). 
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1.2 GENES INFLUENCE SUBSTANCE USE DISORDERS 
Genetic factors have long been recognized to influence the development of substance use 
disorders. Twin studies estimate that the heritability of substance dependence is approximately 
50%-60% (Heath et al., 1997, Kendler et al., 2003, Knopik et al., 2004, Li, 2006). Candidate 
gene studies have identified hundreds of genes potentially associated with substance use 
disorders (Yu et al.). More recently, large-scale genome wide association (GWA) studies have 
confirmed the contribution of a few specific genes to alcoholism and smoking (Wang et al., 
2012, Rietschel and Treutlein, 2013).   
Genes with the clearest associations with alcoholism produce metabolizing enzymes 
(Edenberg and Foroud, 2013, Hurley and Edenberg, 2012). Alcohol is primarily metabolized in 
the liver, and the first step is the oxidation of ethanol to acetaldehyde. Acetaldehyde is a toxic 
intermediate, and systemic build-up leads to unpleasant feelings, such as dizziness, nausea, and 
tachycardia. This process is catalyzed by alcohol dehydrogenases (ADH), which are a class of 
enzymes encoded by seven genes on chromosome 4. The enzyme encoded by ADH1B has the 
highest concentration in adult livers, and the ADH1B rs1229984 variant has reached genome-
wide significance levels for alcohol dependence across different ancestry populations (Li et al., 
2011, Li et al., 2012, Bierut et al., 2012, Gelernter et al., 2014). The minor A allele of rs1229984 
causes an amino acid change at position 48 that increases the rate of oxidation of alcohol and 
leads to transient increases in acetaldehyde. Given the toxicity of acetaldehyde, negative effects 
are experienced by people with this ADH1B variant when they consume alcohol, which 
discourages heavy drinking. 
Similar to alcoholism, nicotine metabolism genes are important for the development of 
smoking behaviors. The cytochrome P450 enzyme CYP2A6 is responsible for the majority of 
5 
 
oxidation of nicotine to cotinine, which is the primary pathway of nicotine metabolism 
(Hukkanen et al., 2005). The region on chromosome 19 that harbors the CYP2A6 gene is 
genome-wide significant in large meta-analyses focused on cigarettes per day (Thorgeirsson et 
al., 2010, TAG, 2010). Among nicotine dependent adults, the majority of studies support that 
genetically slower metabolizers smoke fewer cigarettes per day (Benowitz, 2008), reflecting the 
fact that smokers titrate their cigarette consumption to maintain certain nicotine levels. However, 
studies in youth present conflicting results on the effect of nicotine metabolism on the 
development of nicotine dependence and other smoking behaviors (Audrain-McGovern et al., 
2007, Huang et al., 2005, Moolchan et al., 2009, O'Loughlin et al., 2004, Rubinstein et al., 2013, 
Rubinstein et al., 2008). One challenge to studying CYP2A6 is that the locus is highly 
polymorphic with functionally diverse alleles. Recently, Bloom et al. (2011) developed a 
metabolism metric to predict nicotine metabolism based on different CYP2A6 haplotypes. This 
metric predicts approximately 70% of the variance in metabolism of orally administered nicotine 
to cotinine in European Americans. 
The strongest genetic contribution to nicotine dependence comes from variation in 
nicotinic receptor subunit genes. The physiological effects of nicotine are produced through the 
neuronal nicotinic acetylcholine receptors (nAChRs) (Dani and De Biasi, 2001), which are 
pentamiric catonic channels primarily composed of combinations of α and β subunits. Several 
independent studies have demonstrated that the nonsynonymous rs16969968 variant in the α5 
subunit gene (CHRNA5) is associated with a variety of smoking behaviors (Saccone et al., 2007, 
Berrettini et al., 2008, Weiss et al., 2008, Stevens et al., 2008, Sherva et al., 2008, Baker et al., 
2009, Keskitalo et al., 2009). Subsequently, this association has been reported as the most 
significant in genome-wide meta-analyses of cigarettes per day (p=5.57x10-72) (Thorgeirsson et 
6 
 
al., 2010, TAG, 2010, Liu et al., 2010). Additional studies have extended this association with 
rs16969968 to smoking-related illnesses, including lung cancer and chronic obstructive 
pulmonary disease (Amos et al., 2008, Hung et al., 2008, Pillai et al., 2009, Thorgeirsson et al., 
2008). This association likely reflects greater exposure to carcinogens in tobacco smoke in 
response to higher levels of nicotine dependence. Nicotinic receptors containing α5 subunits 
normally activate the interpeduncular pathway in response to nicotine intake, which discourages 
high levels of cigarette consumption (Fowler et al., 2011). The rs169669968 variant causes an 
amino acid change at position 398, and functional studies show that this change decreases 
receptor function (Bierut et al., 2008, Kuryatov et al., 2011). Decreased function of α5 
containing receptors is hypothesized to prevent negative feedback in response to cigarette 
consumption, leading to heavy smoking. 
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1.3 SCOPE OF THE DISSERTATION 
The primary goal of my dissertation is to improve our understanding of how targeted 
genes contribute to substance use disorders. 
Chapter 2 examines well-studied candidate genes for alcohol dependence using a GWA 
study comparing alcohol dependent cases and controls.  These targeted candidate genes were 
selected using the Human Genome Epidemiology Navigator, which catalogues published genetic 
association studies (Yu et al., 2008).  Our findings suggest that several extensively studied 
candidate loci do not strongly contribute to risk of developing alcohol dependence.  This chapter 
has been published in the Journal Alcoholism: Clinical and Experimental Research (Olfson and 
Bierut, 2012). 
Olfson E, Bierut LJ. Convergence of genome-wide association and candidate gene 
studies for alcoholism. Alcohol Clin Exp Res 2012 36(12):2086-2094. PMCID: 
PMC3521088 
 
Chapter 3 focuses on the interplay between the ADH1B rs1229984 variant and the 
critical social environment of peer drinking in the development of adolescent drinking behaviors. 
Through examining 1,550 European and African American youth enrolled in the Collaborative 
Study on the Genetics of Alcoholism (COGA), we found that this ADH1B variant was protective 
for early drinking milestones, but under the high risk environment of best friends drinking, this 
genetic protection was eliminated. These findings illustrate the important interplay between 
genes and environments in the development of drinking behaviors. This chapter has been 
published in the Journal Alcoholism: Clinical and Experimental Research (Olfson et al., 2014). 
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Olfson E, Edenberg HJ, Nurnberger J Jr, Agrawal A, Bucholz KK, Almasy LA, Chorlian 
D, Dick DM, Hesselbrock VM, Kramer JR, Kuperman S, Porjesz B, Schuckit MA, 
Tischfield JA, Wang JC, Wetherill L, Foroud TM, Rice J, Goate A, Bierut LJ. An 
ADH1B variant and peer drinking in progression to adolescent drinking milestones: 
Evidence of a gene-by-environment interaction. Alcohol Clin Exp Res 2014 Sept 24 
NIHMSID#936008 
 
Chapter 4 assesses the role of CYP2A6 metabolism on the development of smoking 
behaviors during the critical developmental period of young adulthood. By examining over 1,000 
European American young adults enrolled in COGA, we found that the CYP2A6 metabolism 
metric was not associated with smoking initiation or the development of daily smoking, but 
among daily smokers, decreased metabolism was associated with an increased risk of nicotine 
dependence. This finding was replicated in an independent sample of young adult daily smokers 
enrolled in the Collaborative Study of Nicotine Dependence. These results demonstrate the 
complex role of CYP2A6 variation across different developmental stages of smoking behaviors. 
At the time of dissertation defense, this chapter was in preparation for submission. 
Olfson E, Bloom J, Bertelsen S, Breslau N, Budde J, Chen LS, Culverhouse R, Chorlian 
D, Dick DM, Edenberg HJ, Hatsukami D, Hesselbrovck VM, Kramer JR, Kuperman S, 
Porjesz B, Saccone NL, Schuckit MA, Stitzel J, Tischfield JA, Goate A, Bierut LJ. 
CYP2A6 metabolism in the development of nicotine dependence in young adults. 
  
Chapter 5 examines whether CHRNA5 coding variants, beyond the well-studied 
common rs16969968 variant, contribute to nicotine dependence risk. Next-generation 
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sequencing of approximately 3,000 nicotine dependent cases and controls identified the only 
known common variant, 3 low frequency, and 22 rare variants. Our results showed that these 
newly identified variants independently contribute to nicotine dependence risk. Replication of 
common and low frequency variants using 12 independent studies with exome chip data in over 
10,000 heavy and 10,000 light smokers further supported this conclusion. These newly identified 
low frequency and rare variants may have important health implications by influencing risk for 
smoking-related diseases and response to cessation therapies. At the time of dissertation defense, 
this chapter was in preparation for submission. 
Olfson E, Saccone NL, Johnson EO, Chen LS, Culverhouse R, Doheny K, Foltz SM, Fox 
L,  Gogarten SM, Hartz S,  Hetrick K, Laurie CC, Marosy B, Amin N, Arnett D, Bartz 
TM, Bertelsen S, Borecki IB, Brown MR, Chasman DI, van Duijn CM, Feitosa MF, Fox 
ER,  Franceschini N, Franco OH, Grove ML,  Guo X, Hofman A,  Kardia SLR, Morrison 
AC, Musani SK, Psaty BM, Rao DC, Reiner AP, Rice K, Ridker PM, Rose LM, Rotter 
JI, Schick UM, Schwander K, Uitterlinden AG, Vojinovic D, Wang JC, Ware EB, Wilson 
G, Yao J, Zhao W, Breslau N, Hatsukami D, Stitzel J, Rice J, Goate A, Bierut LJ. 
Common, low frequency, and rare coding variants in CHRNA5 contribute to nicotine 
dependence in European and African Americans. 
 
Overall, this work illustrates that although only a limited number of genes clearly 
contribute to substance use, hypothesis-driven analyses can advance our understanding of the 
specific mechanisms by which these genes alter substance use behaviors. In particular, these 
findings illustrate that incorporating environmental factors, critical developmental periods, and 
rare variants may refine associations between robust genes and substance use disorders. 
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CHAPTER TWO: 
Convergence of GWA and candidate gene studies for alcoholism 
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2.1 ABSTRACT 
 
Background: Genome-wide association (GWA) studies have led to a paradigm shift in how 
researchers study the genetics underlying disease. Many GWA studies are now publicly available 
and can be used to examine whether or not previously proposed candidate genes are supported 
by GWA data. This approach is particularly important for the field of alcoholism because the 
contribution of many candidate genes remains controversial. 
 
Methods: Using the Human Genome Epidemiology (HuGE) Navigator, we selected candidate 
genes for alcoholism that have been frequently examined in scientific articles in the past decade. 
Specific candidate loci as well as all the reported SNPs in candidate genes were examined in the 
Study of Alcohol Addiction: Genetics and Addiction (SAGE), a GWA study comparing alcohol 
dependent and non-dependent subjects.  
 
Results: Several commonly reported candidate loci, including rs1800497 in DRD2, rs698 in 
ADH1C, rs1799971 in OPRM1 and rs4680 in COMT, are not replicated in SAGE (p> .05). 
Among candidate loci available for analysis, only rs279858 in GABRA2 (p=0.0052, OR=1.16) 
demonstrated a modest association. Examination of all SNPs reported in SAGE in over 50 
candidate genes revealed no SNPs with large frequency differences between cases and controls 
and the lowest p value of any SNP was .0006.  
 
Discussion: We provide evidence that several extensively studied candidate loci do not have a 
strong contribution to risk of developing alcohol dependence in European and African Ancestry 
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populations. Due to lack of coverage, we were unable to rule out the contribution of other 
variants and these genes and particular loci warrant further investigation.  Our analysis 
demonstrates that publicly available GWA results can be used to better understand which if any 
of previously proposed candidate genes contribute to disease. Furthermore, we illustrate how 
examining the convergence of candidate gene and GWA studies can help elucidate the genetic 
architecture of alcoholism and more generally complex diseases. 
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2.2 INTRODUCTION 
 
Genome-wide association (GWA) studies have revolutionized the search for common 
genetic variants that influence individual risk for complex diseases. Before this revolution, the 
discovery of genetic associations was dominated by candidate gene studies that used targeted 
gene approaches. Examination of these previous gene association studies demonstrates that most 
reported associations are not consistently replicated (Hirschhorn et al., 2002) and the strength of 
genetic associations in initial studies commonly erodes in subsequent research (Ioannidis et al., 
2001). Despite this suggested irreproducibility, many candidate gene association studies continue 
to be published annually (Yu et al., 2008). 
GWA studies rapidly evaluate millions of single nucleotide polymorphisms (SNPs) 
throughout the genome and therefore have the potential for identifying key variants in complex 
diseases. Since the publication of the first GWA study in 2005 (Klein et al., 2005), over 1000 
GWA studies have established genetic associations of more than 200 traits, many of which are 
complex diseases. SNP-trait associations from published GWA studies are readily available to 
investigators through “A Catalog of Genome-Wide Association Studies” by the National Human 
Genome Research Institute (www.genome.gov/gwastudies).  More recently, several datasets 
from GWA studies have also become available to the scientific community through the database 
of Genotypes and Phenotypes (dbGaP) maintained by NCBI (Mailman et al., 2007).  These 
online scientific databases provide opportunities for investigators to access GWA data. 
Online databases can specifically be used to evaluate whether genes that were previously 
suggested in candidate gene studies are replicated in GWA studies. Research by Siontis et al. 
demonstrates that only a few of previously proposed candidate loci of common diseases reached 
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genome-wide significance in GWA studies (Siontis et al., 2010). The loci that did replicate, 
however, had important genetic effects and included variants implicated in Alzheimer’s disease 
and statin-induced myopathy. Similarly, a recent analysis by Obeidat et al. examined genetic 
associations with lung function measures to evaluate the role of previously associated genes in a 
large GWA study and clarified the role of many controversial associations (Obeidat et al., 2011). 
This approach of comparing candidate gene and GWA studies is powerful because it highlights 
which findings have consistent scientific evidence and therefore merit being pursued in future 
studies. These findings prompted us to examine whether proposed candidate genes associated 
with alcohol dependence are supported by GWA data.  
Genetic and environmental factors contribute to individual susceptibility to alcohol 
dependence. Twin studies estimate that heritable influences explain 47-64% of variance in risk 
for alcohol dependence (Heath et al., 1997; Knopik et al., 2004). Several past research efforts 
have focused on targeted gene approaches to shed light on the genes that underlie these heritable 
influences. This has led to the proposal of hundreds of candidate genes that contribute to the 
development of alcohol dependence (Yu et al., 2008). A few GWA studies have also explored 
genes potentially involved in alcohol dependence (Bierut et al., 2010; Edenberg et al., 2010; 
Farrer et al., 2009; Heath et al., 2011; Hodgkinson et al., 2010; Joslyn et al., 2010; Treutlein et 
al., 2009; Zlojutro et al., 2011). Despite extensive candidate gene studies and several GWA 
studies, little consensus exists over which if any genes contribute to the genetic basis of alcohol 
dependence. 
The existence of many controversial candidate genes for alcoholism highlights the need 
for further research on whether or not these genes replicate in large datasets. Results from the 
Study of Alcohol Addiction: Genetics and Addiction (SAGE) have recently become available 
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through dbGaP. SAGE compares DSM-IV alcohol dependent individuals and non-dependent, 
unrelated control subjects of European and African American descent. Using the SAGE data, we 
examined differences in SNP frequencies between cases and controls within previously reported 
candidate genes. These targeted candidate genes were selected using the Human Genome 
Epidemiology (HuGE) Navigator, a publicly searchable database established in 2001 of 
published genetic association and human genome epidemiological studies (Yu et al., 2008).  The 
HuGE Navigator along with the SAGE results facilitated the systematic examination of 
candidate genes considered in many alcoholism studies over the last decade.  
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2.3 MATERIALS AND METHODS 
 
Selection of Candidate Genes  
The HuGE Navigator was developed using PubMed abstracts as the core data source and 
using data and text mining algorithms to develop a knowledge database (Yu et al., 2008). Each 
week since 2001, articles are systematically deposited in the database and represent a 
comprehensive list of recent articles.  An automatic literature program screens PubMed for 
abstracts and then a genetic epidemiologist selects abstracts meeting inclusion criteria and 
indexes them. Phenopedia of the HuGE Navigator gives a disease-centered view of genetic 
association studies by providing information about genes studied in relation to a queried 
phenotype (Yu et al., 2010). Phenopedia was queried in July 2011 for Alcoholism and 584 genes 
were retrieved.  
We focused our study on genes that have been frequently characterized by candidate gene 
studies. In primary analysis, over 90% of the genes associated with alcoholism in the HuGE 
database have 5 or fewer publications (528 out of 584 genes). The 56 candidate genes that have 
more than 5 publications vary substantially in the number of publications (6-103 publications). 
Figure 2.1A highlights that many genes have one or a few reported publications and there are 
some outliers that have been examined in many papers. This distribution may be explained in 
part by the fact that many of the genes with a low number of publications have been primarily 
identified in a GWA study and are not well characterized in targeted candidate gene studies. 
Figure 2.1B demonstrates that for almost 50% (176/386) of the genes with one publication that 
publication is itself a GWA study. Based on these preliminary observations, we narrowed our 
investigation to genes with more than 5 publications to focus our analysis on well-studied genes.   
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Since the X chromosome is not included in the publicly available SAGE results, the two 
candidate genes on the X chromosome MAOA and HTR2C, which have 26 and 8 publications 
respectively, were excluded from the analysis. The 54 autosomal genes that had more than 5 
publications were pursued using the SAGE dataset. For the remainder of this paper, we will only 
refer to the 54 autosomal candidate genes. 
 
SAGE Data 
SAGE is a case-control study that analyzed genetic data on over 3,800 phenotyped 
subjects funded as part of the Gene Environment Association Studies (GENEVA) initiative 
supported by the National Human Genome Research Institute (Bierut et al., 2010). Alcohol-
dependent cases and controls were selected from three large datasets: the Collaborative Study on 
the Genetic of Alcoholism (COGA), the Family Study of Cocaine dependence (FSCD) and the 
Collaborative Genetic Study of Nicotine Dependence (COGEND). Cases are required to have a 
lifetime history of DSM-IV alcohol dependence. Controls are required to have been exposed to 
alcohol because alcohol use is necessary to develop dependence, but not to have met lifetime 
diagnosis criteria for alcohol dependence or dependence for illicit drugs. A common assessment 
was performed for all cases and controls in the three studies that was based on the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz et al., 1994). The 
common methodology of interview administration, question format and queried domains enabled 
phenotypic standardization across the three studies (Bierut et al., 2010). Characteristics of the 
cases and controls in the SAGE dataset are listed in Table 2.1 and additional information is 
available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
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bin/study.cgi?study_id=phs000092.v1.p1. The SAGE dataset is publicly searchable through the 
Genome Brower under the Analysis tab on this website.  
The power Calculator for Association with Two Stage design (CATS) was used to 
determine what effect sizes the SAGE dataset is able to detect (Skol et al., 2006). Using a sample 
size of 1900 cases and 1900 controls and an alpha level of .05, we calculated different allele 
frequencies and risk ratios. 
 
Examination of SNPs in Candidate Genes 
The HuGE database was used to survey articles on the ten candidate genes that had the 
most publications (listed in Table 2.2). The most well established loci based on expert opinion of 
the literature for each of the top ten candidate genes was searched in the genome browser to test 
whether candidate loci that had been highly reported in candidate gene studies replicated in the 
SAGE dataset. Since allele A9 for SLC6A3 is a VNTR, we examined the two SNPs rs27072 and 
rs27048 as proxies because they have been found to be associated with similar withdrawal 
symptoms and are roughly in the same region of the gene as the VNTR (Le Strat et al., 2008). As 
the originators of the SAGE dataset, we were also able to compare the odds ratios and p values 
within the original three datasets (COGA, FSCD and COGEND) to verify whether there was any 
heterogeneity across the three contributing studies. 
The 54 candidate genes with more than 5 publications were identified and chromosomal 
regions containing the gene plus 10 kb both 5’ and 3’ of the gene were examined. These 
expanded regions were searched using the SAGE genome browser and SNPs within these 
regions with p<.05 were recorded.  
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For each candidate gene, all SNPs with p<.05 were queried together in SNP Annotation 
and Proxy Search (SNAP) to assess linkage disequilibrium (Johnson et al., 2008). These searches 
were performed using the 1000 genomes pilot 1 SNP dataset, an r2 > .8, and a distance limit of 
500. This analysis was performed with both the CEU and YPI population panels separately 
because of allele frequency differences between European American and African American 
subsets.  All SNPs that had an r2 greater than 0.8 and at least one other variant in a group were 
considered a cluster.  
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2.4 RESULTS 
 
The SAGE dataset contains half of the most commonly reported variants associated with 
the ten most well studied candidate genes (Table 2.2). Of the 5 candidate variants reported in 
SAGE, the only variant with a p< .05 is rs279858 in GABRA2 (p=.0052, OR=1.16). The 
commonly reported variants, rs1800497 in DRD2, rs698 in ADH1C, rs1799971 in OPRM1 and 
rs4680 in COMT, have p> .05. The minor allele for rs17999971 in OPRM1 trends towards being 
protective (OR=.88) while the minor alleles of rs1800497 in DRD2, rs698 in ADH1C and rs4680 
in COMT trend toward being associated with alcohol dependence (OR=1.11,1.08,1.02 
respectively). The effects of these associations are in the expected direction based on previous 
candidate gene studies (Blum et al., 1990; Bond et al., 1998; Hendershot et al., 2011; Ponce et 
al., 2008; Thomasson et al., 1991; Tiihonen et al., 1999; Tolstrup et al., 2008; Zhang et al., 
2006). In addition, these effects in SAGE were similar to the findings in the individual three 
studies that contributed to SAGE: COGA, FSCD and COGEND.  Across the three contributing 
studies, the odds ratios ranged from 1.07-1.13 for rs1800497 in DRD2, 1.06-1.11 for rs698 in 
ADH1C, 0.82-0.95 for rs1799971 in OPRM1, 1.09-1.17 for rs279858 in GABRA2 and 1.02-1.09 
for rs4680 in COMT (data not shown). 
Several commonly reported variants associated with alcoholism are not on the Illumina 
chip that was used to generate the SAGE dataset. These SNPs include rs671 in ALDH2, 
rs1229984 in ADH1B, rs4795541 in SLC6A4 and rs3813867 in CYP2E1. Since the A9 allele in 
SLC6A3 is a VNTR and therefore also not reported in SAGE, we examined two proxy SNPs (Le 
Strat et al., 2008). Neither of these two SNPs show a significant difference between the cases and 
controls  (p=.8646 for rs27072 and p=.3842 for rs27048). 
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In every gene with more than 5 publications, few SNPs had impressive differences 
between cases and controls. Of the 2175 SNPs reported in the 54 genes with more than 5 
publications, approximately 5% have a p<.05 (116/2175) and approximately 1% have a p<.01 
(16/2175) (Table 2.3). The lowest p value of any variant was 0.0006 for rs925946, which is a 
SNP upstream of BDNF. 
In a few genes, a large proportion of the SNPs have modest frequency differences 
between cases and controls. In 10 out of the 54 genes examined, more than 10% of the SNPs 
have p<.05 and in 3 genes this portion exceeds 20%. Specifically, the proportion of SNPs in 
SAGE with p<.05 is 55% (16/29) in GABRA2, 24% (10/29) in BDNF and 44% (4/9) in HTR1A 
(Table 2.3).  To test whether the large proportion of SNPs with small p values in these genes 
could be explained by linkage disequilibrium, we performed SNAP analyses.  
Many variants clustered as defined by r2> 0.8 within the genes but the proportion of 
clusters containing SNPs with p<.05 remained quite similar with SNAP analyses in both CEU 
and YPI populations (data not shown).  Of the variants with linkage disequilibrium data available 
in SNAP for the CEU population, 27 SNPs in GABRA2 broke down into 10 clusters of which 5 
clusters had SNPs with p<.05 (50%), 24 SNPs in BDNF broke down into 9 clusters of which 4 
clusters had SNPs with p<.05 (44%), and 6 SNPs in HTR1A broke down into 3 clusters of which 
1 cluster had SNPs with p<.05 (33%). Generally fewer SNPs clustered in the YRI population 
than in the CEU population but the proportion of clusters containing SNPs with p<.05 was 
comparable between the two populations. In the YRI population, 25 SNPs in GABRA2 broke 
down into 16 clusters of which 12 clusters had SNPs with p<.05 (75%), 25 SNPs in BDNF broke 
down into 19 clusters of which 10 clusters had SNPs with p<.05 (53%), and 9 SNPs in HTR1A 
broke down into 5 clusters of which 2 cluster had SNPs with p<.05 (40%). 
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 Power calculations demonstrate that the SAGE dataset has 90% power with an alpha 
level of .05 to detect a genetic variant with a minor allele frequency of .10 and an odds ratio of 
1.25 or greater. The dataset also has 90% power with an alpha level of .05 to detect a variant 
with a minor allele frequency of .40 and an odds ratio of 1.15 or greater. 
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2.5 DISCUSSION 
 
Over the last decade, hundreds of candidate genes have been proposed for alcoholism. 
We used local and global approaches to specifically investigate variants within the most widely 
studied of previously proposed candidate genes. Our primary finding is that most of these 
candidate genes are not strongly supported by GWA data. This observation reduces the 
likelihood that these previously proposed genes individually have a strong effect on the genetic 
risk of alcohol dependence. The results mirror prior work that most candidate loci in common 
diseases are not strongly replicated in GWA studies except for a few biologically important 
variants (Siontis et al., 2010; Obeidat et al., 2011).  
Analysis of well-characterized loci that were previously proposed in candidate gene 
studies in a large GWA study on alcoholism, SAGE, reveals unimpressive differences between 
cases and controls at most loci. The frequently studied variants associated with alcoholism in 
DRD2, ADH1C, OPRM1 and COMT demonstrate insignificant frequency differences in SAGE 
(p>.05, Table 2.2). Although several studies implicate a biological role of these variants in 
alcoholism (Blum et al., 1990; Bond et al., 1998; Hendershot et al., 2011; Ponce et al., 2008; 
Thomasson et al., 1991; Tiihonen et al., 1999; Tolstrup et al., 2008; Zhang et al., 2006), our 
results reveal that these variants are not strongly associated with alcoholism in European and 
African ancestry populations. The only candidate that modestly replicated in SAGE, rs279858 in 
GABRA2, had a p-value of 0.0052 (OR=1.572). This finding was anticipated because a previous 
GWA study on the SAGE dataset demonstrated a similar association (Bierut et al., 2010). The 
replication of rs279858 in SAGE provides some support for future studies focused on the 
function of this variant and associated variants in GABRA2 (Edenberg et al., 2004).  
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When examined globally, none of the well-studied candidate genes demonstrate 
impressive variant differences between cases and controls. More specifically, only one SNP 
reported in SAGE (rs925946 upstream of BDNF, p=0.0006) in the 54 candidate genes had a p 
value less than 0.0009, a corrected p value for the number of genes (.05/54= 0.0009). 
Additionally, the overall number of variants with p<.05 and p<.01 is close to that predicted by 
chance considering the total number of SNPs examined in all proposed candidate genes. 
Although the individual p values for variants in the examined candidate genes are modest, a few 
candidate genes have a large portion of SNPs with p<.05 (Table 2.3). The results support further 
research into whether GABRA2, which was the candidate gene with the largest proportion of 
SNPs with p< .05 (55%), contributes to risk of developing alcohol dependence. BDNF and 
HTR1A also had more than one fifth of SNPs with p<.05, indicating that these genes merit 
further investigation to elucidate their potential contribution to alcohol dependence.  
Lack of replication in SAGE does not exclude the possibility that some previously 
proposed candidate genes and specific loci are biologically important.  Several of the most well 
studied candidate loci for alcoholism were not available in SAGE, including rs671 in ALDH2, 
rs1229984 in ADH1B, rs4795541 in SLC6A4 and rs3813867 in CYP2E1. A recent study that 
specifically genotyped rs1229984 in SAGE reported that the minor allele has a significant 
protective effect on alcohol dependence ( p=6.6x 10-10) (Bierut et al., 2011).  Because rs1229984 
is common in Asians but rare in European Americans, this variant in ADH1B was not genotyped 
in the original GWA study. This highlights that GWA studies may miss important variants 
because of lack of coverage of SNPs that are uncommon in European American populations. 
Additionally, GWA studies cannot assess all forms of inheritance that can be associated with 
candidate genes such as insertion/deletion mutations, copy number repeats and epigenetic 
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changes.  Although SAGE is a valuable tool, it cannot exclude the possibility that aspects of 
genes contribute to genetic risk of alcohol dependence. 
Even though the well studied candidate variants in DRD2, ADH1C, OPRM1 and COMT 
were not significantly associated with alcohol dependence in SAGE, their odds ratios were in the 
expected direction based on previous candidate gene studies. More specifically, the odds ratio of 
0.088 for rs1799971 in OPRM1 supports previous studies that the minor allele variant is 
protective against alcohol dependence (Bond et al., 1998; Zhang et al., 2006) while the odds 
ratios greater than 1 for rs1800497 in DRD2, rs698 in ADH1C, and rs4680 in COMT supports 
previous studies that the minor allele of these variants are more common in alcohol dependent 
individuals (Blum et al., 1990; Hendershot et al., 2011; Ponce et al., 2008; Thomasson et al., 
1991; Tiihonen et al., 1999; Tolstrup et al., 2008). The fact that these odds ratios are in the 
expected direction but did not pass a threshold of .05 for significance may suggest that these 
variants have a small contribution to alcohol dependence and this study lacked the power to 
detect the association. 
Our study design had several strengths. First, the literature search for candidate genes 
included all genetic associations irrespective of ethnicity and criteria for alcoholism. By 
including all genes with the most genetic association study publications, we comprehensively 
examined previously identified genes associated with alcoholism in a large GWA study on 
alcoholism. Second, the SAGE dataset has the power to detect associations of small magnitude. 
SAGE included more than 3,800 subjects and had 90% power to detect a genetic variant with an 
odds ratio of 1.25 for a risk locus with 10% minor allele frequency. Third, our findings in SAGE 
regarding the well-characterized loci were found to be very similar to the results in the three 
independent datasets that contributed to SAGE, which indicates that there is no heterogeneity 
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across these datasets. Fourth, our approach used data that is available to the scientific community 
and can be easily replicated in future studies of other phenotypes. 
Despite these strengths, the selection of candidate loci and genes based on number of 
publications retrieved by the HuGE Navigator Phenopedia has some limitations.  One limitation 
is that no data suggests that the potential significance of a given gene is directly proportional to 
the number of publications. Despite this, we felt that the number of publications is an indicator of 
research efforts devoted to a given gene. By selecting genes with the most publications, we 
sought to capture well-studied genes that had been the focus of the field in the past. A second 
potential limitation is that we did not exclude publications based on the same datasets. Because 
we used a low threshold of greater than 5 publications in the initial analysis, however, we are 
confident that we did not exclude any genes that have been examined in many studies. 
Additionally, the most well-studied loci of the ten genes with the most publications were selected 
based on expert opinion and were felt to be unambiguously widely studied even if the exact order 
may not be reflective of the number of data sets published on the genes. 
Beyond limitations in our selection of candidate genes, the SAGE dataset has limitations 
that restrict the interpretation of our results. First, some of the most well studied variants were 
not covered in SAGE and therefore could not be assessed. Second, the X chromosome is not 
included in the publically available SAGE results so we were unable to investigate genes on the 
X chromosome. Specifically, two candidate genes on the X chromosome, MAOA and HTR2C 
that had 26 and 8 publications respectively, were not assessed. Third, SAGE is limited in its 
power to identify genotyped variants on the GWA chip that have small effect sizes. Despite the 
fact that the SAGE dataset was relatively large when it was originally published, identifying 
common variants with small effect sizes (<1.1) remains challenging and we are unable to rule out 
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the possibility of real but modest effects of these genes. Forth, variants that are uncommon (1%-
5%) or rare (<1%) in the study population may also not be detected in SAGE because of their 
individually small contribution to overall alcoholism.  Fifth, the SAGE dataset primarily consists 
of European Americans (69.5%), African Americans (30.3%) and a few Hispanics (3.4%) (Table 
2.1) and association findings may be different in other populations such as Asians. Some of the 
genes and variants examined in this analysis are more well studied and have a higher frequency 
in Asian Ancestry than in European and African Ancestry populations, such as the Asp40 allele 
of the candidate variant rs1799971 in OPRM1 (Arias et al., 2006), and therefore may have a 
more impressive effect in studies that focus on Asian ancestry populations. Sixth, our analysis 
did not examine the effects of combinations of genes or the effect of different environmental 
factors. Analysis of multiple genes and populations enriched for specific environmental risk 
factors will likely explain a greater degree of the genetic risk of alcoholism. Despite these 
limitations, this analysis demonstrates that GWA studies are a powerful technique for verifying 
the importance of genes and particular variants that have been previously identified in the 
candidate gene era. 
In summary, we provide evidence that for alcohol dependence, several extensively 
studied candidate loci and genes are not replicated in a large GWA study, indicating that these 
variants do not individually have a large contribution to risk of developing alcohol dependence in 
European and African ancestry populations. Our analysis was unable to rule out the possibility 
that some variants and genes are important for risk of alcoholism due to lack of coverage. Recent 
work demonstrates that at least one highly reported variant rs1229984 in ADH1B that is not 
reported in SAGE is significantly associated with alcoholism (Bierut et al., 2011), suggesting the 
possible importance of further research on highly supported variants that cannot be assessed in 
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SAGE.  Our approach may also have missed variants that have a real but small individual 
contribution to overall inheritance of alcoholism.  
This analysis demonstrates that targeted candidate gene studies and GWA studies each 
provide important information and studying the convergence of these two experimental designs 
has the potential to advance understanding of the etiology of alcohol dependence and more 
generally complex diseases. While GWA studies provide important information about the 
genetic contribution of common variants to complex diseases across populations, hypothesis 
driven candidate gene studies are also important to assess variants of lesser significance that may 
be missed because of the strict p value thresholds required for the large number of comparisons 
in GWA studies. Incorporating knowledge from both GWA and candidate gene studies will help 
clarify the role of genetics in complex disease and guide future research.  
Our study also shows how the HuGE Navigator and dbGaP databases can be used as 
tools by researchers to easily access and analyze information on candidate genes and GWA data. 
Beyond alcoholism, the HuGE Navigator provides an easy way for investigators to search over 
2,000 diseases and 10,000 genes for summary information and primary articles about genetic 
associations and human genome epidemiology (Yu et al., 2008).  The dbGaP database provides 
access to results of over 100 studies examining phenotype and genotype associations, including 
40 GWAS studies on different diseases. Since dbGaP currently contains a limited number of 
GWA studies, researchers examining phenotypes not available in dbGaP may benefit from 
directly contacting the authors of relevant GWA studies and meta analysis.  Because of this easy 
accessibility, researchers who intend to perform future candidate gene studies should reference 
the HuGE navigator to assess background information and use dbGaP and existing GWA data to 
test whether their gene of interest is replicated in GWA data.  Candidate gene studies need 
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replication to meet scientific standards. Simple dbGaP analyses may help to focus future research 
on genes that are supported by GWA data and therefore more likely to be biologically important 
for human disease.  
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2.8 TABLES 
Table 2.1.  Characteristics of alcohol dependent cases and non-dependent controls in SAGE 
Characteristic Cases n=1,897 Controls n=1,932 Total n=3,829 
Sex, n (%)    
    Males 1.155 (60.9) 606 (31.4)* 1,761 (46.0) 
    Females 742 (39.1) 1,326 (68.6) 2,068 (54.0) 
Age, years    
   Mean + SD 39.0 + 9.3 39.3 + 9.1 19.2 + 9.2 
   Range 18.0-77.0 18.0-65.0 18.0-77.0 
Self-reported race, n (%)    
    European-American 1,235 (65.1) 1,433 (74.2)* 2,668 (69.5) 
    African-American 662 (34.9) 499 (25.8) 1,161 (30.3) 
Self-reported ethnicity, n (%)    
   Hispanic 76 (4.0) 56 (2.8) 132 (3.4) 
Alcohol dependence    
   Diagnosis, n (%) 1,897 (100.0) 0 (0.0)* 1,897 (49.5) 
 
Sex, age, race, ethnicity and alcohol dependence characteristics of cases and controls in the 
Study of Alcohol Addiction: Genetics and Addiction (SAGE) dataset (Bierut et al., 2010). 
* p<0.0001 for difference between cases and controls  
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Table 2.2.  Examination of Top Ten Candidate Loci for Alcoholism in SAGE 
Candidate 
Genes 
Publications on 
Alcoholism 
association 
Commonly 
reported SNP 
Common Name of SNP  P value in 
SAGE 
Odds Ratio in  
SAGE (CI) 
ALDH2 103 rs671 
ALDH2*2  
 (Harada, 1982) - - 
ADH1B  89 rs1229984 
  
ADH1B*2/ADH2*2 
(Thomasson, 1992) - - 
DRD2   83 rs1800497  
 
TaqIA  
(Blum, 1990) 0.09 1.1053 (.9845-1.2408) 
SLC6A4 83 rs4795541 
 
5-HTTLPR/S allele 
(Sander, 1997) - - 
ADH1C  51 rs698 
 
ADH1C*2  
(Thomasson, 1992) 0.1452 1.0819 (.9732-1.2028) 
OPRM1  38 rs1799971 
 
Ala118Gly  
(Bond, 1998) 0.1372 .8823 (.7481-1.0407) 
CYP2E1 35 rs3813867 
 
CYPE1*c2  
(Hayashi, 1991) - - 
GABRA2 27  rs279858* 
 
 (Edenberg,  2004) 0.0052 1.1572 (1.0445-1.2821) 
COMT  26 rs4680 
 
Val158Met  
(Tiihonen, 1999)  0.6328 1.0244 (.9278-1.1311) 
SLC6A3 
 
25 
 
**  
 
 
A9 (VNTR)   
(Dobashi, 1997) 
    	
In the ten most frequently studied genes associated with alcoholism according to the Human 
Genome Epidemiology (HuGE) Navigator, the most well studied variants were examined in 
Study of Alcohol Addiction: Genetics and Addiction (SAGE). 
*One of over 20 SNPs significantly associated with alcohol dependence (Edenberg et al., 2004). 
This SNP was examined because it was the only one in an exon. 
**Examined 2 SNPs, rs27072 and rs27048, as proxies (Le Strat et al., 2008) 
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Table 2.3. SNPs in frequently studied candidate genes associated with Alcoholism  
Candidate 
Genes 
Publications on 
Alcoholism  
SNPs recorded 
in dbSNP  
 Total SNPs in 
SAGE  
SNPs in SAGE 
p<.05 p<.01 p<.005  p<.001 
ALDH2 103 407 24 - - - - 
ADH1B  89 337 21 - - - - 
DRD2   83 826 41 7 1 - - 
SLC6A4 83 637 21 2 - - - 
ADH1C  51 522 29 1 - - - 
OPRM1  38 3568 122 4 - - - 
CYP2E1 35 210 49 - - - - 
GABRA2 27 1692 29 16 5 1 - 
COMT  26 752 55 - - - - 
SLC6A3 25 1322 38 - - - - 
HTR2A  22 1036 61 8 - - - 
HTR1B  18 60 12 2 1 - - 
DRD4   18 184 9 - - - - 
BDNF  16 624 29 10 2 2 1 
NPY   15 241 19 2 - - - 
DRD3  14 693 31 3 - - - 
APOE 13 106 12 1 - - - 
MTHFR 13 324 49 - - - - 
GABRA6 13 215 18 - - - - 
TPH1  13 277 14 - - - - 
GRIN2B 12 5233 245 11 4 3 - 
CNR1  12 2778 27 5 2 - - 
TPH2  11 1415 54 1 - - - 
ADH4    10 830 62 1 - - - 
CHRM2   10 1992 62 3 - - - 
CRHR1   9 1183 26 1 - - - 
ANKK1   9 218 26 4 - - - 
ALDH1A1 9 739 122 3 - - - 
DRD1    9 82 19 - - - - 
GABRG2  9 991 30 - - - - 
GABRB2 9 2699 80 1 - - - 
HTR1A   9 45 9 4 - - - 
GSTM1   9 123 3 - - - - 
OPRD1   9 585 20 1 - - - 
OPRK1   9 226 37 - - - - 
GABRB3  8 23 104 9 1 - - 
GABRA1  8 583 20 - - - - 
DBH   8 562 47 1 - - - 
ADH1A  8 293 19 2 - - - 
ADH5    7 584 38 - - - - 
GAD1    7 692 31 1 - - - 
HFE      7 188 28 1 - - - 
GRIN1    6 513 18 - - - - 
GAD2     6 784 49 1 - - - 
GABRB1   6 4354 111 2 - - - 
ADH7     6 288 32 - - - - 
ADRA2A  6 46 9 - - - - 
CHRNA5 6 254 16 - - - - 
POMC    6 102 10 - - - - 
SLC6A2  6 837 49 1 - - - 
CCKBR   6 300 20 4 - - - 
CCKAR   6 167 15 - - - - 
TNF      6 177 36 2 - - - 
CCK      6 461 18 1 - - - 
Total (n=54)     2175 116 16 6 1 
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All genes with more than 5 publications in Human Genome Epidemiology (HuGE) Navigator 
were examined in Study of Alcohol Addiction: Genetics and Addiction (SAGE). Genes were 
expanded by 10 kb on both sides before they were queried in the SAGE database. MAOA and 
HTR2C were excluded because they were on the X chromosome. 
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2.9 FIGURES 
 
 
Figure 2.1. Characteristics of genes associated with Alcoholism in the Human Genome 
Epidemiology (HuGE) Navigator (A) Distribution of number of publications on genes;  (B) 
Proportion of genes observed in at least one GWA study stratified based on number of 
publications. 4 genes were identified in 2 GWA study (these genes had 2, 2, 10 and 51 
publications).  All other genes were found in 1 or none GWA study. A total of 8 GWA studies on 
Alcoholism are listed in the HuGE database (Bierut et al., 2010; Edenberg et al., 2010; Farrer et 
al., 2009; Heath et al., 2011; Hodgkinson et al., 2010; Joslyn et al., 2010; Treutlein et al., 2009; 
Zlojutro et al., 2011). 
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CHAPTER THREE: 
An ADH1B variant and peer drinking in progression to adolescent drinking milestones:  
Evidence of a gene-by-environment interaction 
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3.1 ABSTRACT 
 
Background: Adolescent drinking is an important public health concern, one that is influenced 
by both genetic and environmental factors. The functional variant rs1229984 in alcohol 
dehydrogenase 1B (ADH1B) has been associated at a genome-wide level with alcohol use 
disorders in diverse adult populations. However, few data are available regarding whether this 
variant influences early drinking behaviors and whether social context moderates this effect. This 
study examines the interplay between rs1229984 and peer drinking in the development of 
adolescent drinking milestones.  
 
Methods: 1,550 European and African American individuals who had a full drink of alcohol 
before age 18 were selected from a longitudinal study of youth as part of the Collaborative Study 
on the Genetics of Alcoholism (COGA). Cox proportional hazards regression, with GxE product 
terms in the final models, was used to study two primary outcomes during adolescence: age of 
first intoxication and age of first DSM-5 alcohol use disorder symptom. 
 
Results: The minor A allele of rs1229984 was associated with a protective effect for first 
intoxication (HR=0.56, 95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.26-
0.77) in the final models. Reporting that most or all best friends drink was associated with a 
hazardous effect for first intoxication (HR=1.81, 95% CI 1.62-2.01) and first DSM-5 symptom 
(HR=2.17, 95% 1.88-2.50) in the final models. Furthermore, there was a significant GxE 
interaction for first intoxication (p=.002) and first DSM-5 symptom (p=.01). Among individuals 
reporting none or few best friends drinking, the ADH1B variant had a protective effect for 
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adolescent drinking milestones, but for those reporting most or all best friends drinking, this 
effect was greatly reduced. 
 
Conclusions: Our results suggest that the risk factor of best friends drinking attenuates the 
protective effect of a well-established ADH1B variant for two adolescent drinking behaviors. 
These findings illustrate the interplay between genetic and environmental factors in the 
development of drinking milestones during adolescence. 
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3.2 INTRODUCTION 
 
By age 17, most U.S. adolescents (54%-78%) have consumed alcohol, and a significant 
proportion (15%) meet the criteria for alcohol abuse (Merikangas et al., 2010; NSDUH, 2012; 
Swendsen et al., 2012). Patterns of alcohol use that begin in adolescence are important 
determinants for the development of alcohol use disorders during adulthood (Grant et al., 2006; 
Pitkanen et al., 2005). Therefore, understanding factors that contribute to early drinking 
behaviors is critical for disease prevention. 
For decades, twin studies have recognized that both genetic and environmental factors 
influence individual risk for alcoholism (Heath et al., 1997; Kendler et al., 1994; Pickens et al., 
1991; Prescott and Kendler, 1999). Recently, large-scale genetic studies have provided strong 
evidence for the contribution of specific genetic variants to alcohol use disorders in adults 
(Rietschel and Treutlein, 2013; Wang et al., 2012). An important next step in the translation of 
genetic findings identified in adults is to test whether these genetic variants also affect adolescent 
drinking behaviors and whether environmental risk factors moderate this role. 
Among the most biologically well-understood genetic variants associated with alcohol 
use disorders is the polymorphism rs1229984 in the enzyme alcohol dehydrogenase 1B 
(ADH1B). The minor A allele (in the coding strand) of rs1229984 causes an amino acid change 
at position 48 by replacing arginine with histidine, which increases the activity of the ADH1B 
enzyme that oxidizes ethanol to acetaldehyde (Edenberg and Foroud, 2013; Hurley and 
Edenberg, 2012). After consuming alcohol, elevated ADH1B activity has been hypothesized to 
transiently increase the level of acetaldehyde, leading to unpleasant effects that limit further 
drinking. Meta-analysis of this variant in Asian populations, where the rs1229984 A allele is 
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common (allele frequency=0.7 in 1000 Genomes)(Abecasis et al., 2012), has demonstrated 
strong effects on the risk of developing alcohol-related disorders (OR 0.45: p=7x10-42) (Li et al., 
2011).  Recently, this polymorphism was shown to have a similar effect on risk of alcohol 
dependence in European and African Americans (African and European OR 0.34: p=6.6x10-10 
(Bierut et al., 2012); European: p=1.17x10-31(Gelernter et al., 2014)), where the rs1229984 A 
allele is less common (European American frequency=0.05; African American frequency=0.02 
in Exome Variant Server)(http://evs.gs.washington.edu/EVS/).   
Other studies suggest that social environments that encourage drinking may diminish the 
protective genetic effects of alcohol metabolizing variants (Hasin et al., 2002; Higuchi et al., 
1994; Irons et al., 2007; Irons et al., 2012). However, to our knowledge, no study has explored 
the interplay of the ADH1B rs1229984 variant and the important social context of peer drinking 
during the critical developmental period of adolescence when alcohol use is initiated and 
drinking patterns are established. Peer drinking has long been recognized as a strong risk factor 
for adolescent drinking problems (Curran et al., 1997; Reifman et al., 1998), and recently, twin 
studies have provided evidence that peer drinking modifies heritable variation in adolescent 
alcohol involvement (Agrawal et al., 2010; Dick et al., 2007; Guo et al., 2009; Harden et al., 
2008).   
This study tests the interaction between a genome-wide significant functional ADH1B 
variant and the risk environment of peer drinking in the development of two adolescent drinking 
milestones: first intoxication and first DSM-5 alcohol use disorder symptom. Examining 
hypothesis-driven gene-by-environment (GxE) interactions using robust genetic and 
environmental risks during developmental transitions provides an important approach for 
untangling the complex etiology of alcohol use disorder. 
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3.3 MATERIALS AND METHODS 
 
COGA Sample Description 
Study participants were enrolled in the Collaborative Study on the Genetics of 
Alcoholism (COGA), a large, multi-center, family study designed to identify genes that 
contribute to alcohol use disorders in high-risk (defined as recruited through alcohol dependent 
probands) and community comparison families (Begleiter et al., 1995). Since 2005, the 
adolescent and young adult study in COGA has used a longitudinal design to examine the 
development of alcohol use disorders in young participants from these families. Individuals aged 
12 to 22 were recruited from six sites across the US and interviewed every two years. 
Institutional review boards at all sites approved the study design. Adult participants provided 
informed consent, parents provided consent for all children younger than 18, and children 
provided assent. 
 
Assessment of Phenotypes 
Interview assessment was performed using the Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA) to gather reliable and valid information on alcohol use 
behaviors (Bucholz et al., 1995; Bucholz et al., 1994; Hesselbrock et al., 1999). Participants 18 
years and older were assessed with the Phase IV SSAGA, and those less than 18 years were 
assessed with an age appropriate adolescent version called the Phase IV C-SSAGA (Kuperman 
et al., 2001). 
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Drinking Milestones 
Two adolescent drinking milestones were used as primary outcomes among adolescent 
ever-drinkers: age of first intoxication, a common and clinically relevant variable, and first 
DSM-5 alcohol use disorder symptom, a heritable characteristic associated with future alcohol-
related problems (Rhee et al., 2003; Young et al., 2006). These outcomes commonly occur 
during adolescence and therefore coincide with the environment of adolescent peer drinking.  
Age of first intoxication was derived from responses to the question “How old were you the first 
time you got drunk, that is, your speech was slurred or you were unsteady on your feet?” Age of 
first DSM-5 symptom was developed from examining the youngest age that individuals first 
experienced one of the 11 symptoms of alcohol use disorder.  Given the longitudinal design of 
this study with multiple assessments over time, the earliest interview in which the participant 
endorsed first intoxication or first DSM-5 symptom was selected to assign the age of onset.   
 
Peer Drinking 
The environment of adolescent peer drinking was derived from participant responses to 
questions addressing the proportion of best friends who drink.  With the longitudinal design of 
the study, 88% (1366/1550) of participants received at least one adult SSAGA assessment at age 
18 years or older.  Assignment of the level of peer drinking in these participants was determined 
from the first adult SSAGA interview with the question “When you were 12-17, how many of 
your best friends used alcohol?” and the 4 possible answers of none, few, most, or all.  For 
participants who had not reached age 18 at the last assessment, peer drinking was evaluated with 
the maximum value from all C-SSAGA answers to the question “How many of your best friends 
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use alcohol?”   For the primary analyses, peer drinking was dichotomized into low peer drinking 
(few or no best friends drink) and high peer drinking (most or all best friends drink) as done in 
previous studies (Kuperman et al., 2013). The four level peer drinking variable (none, few, most, 
or all best friends) was also investigated in secondary analyses to assess a possible dose 
response, but interaction effects are not presented because of the small number of individuals in 
some groups. 
To assess the concordance of the retrospective SSAGA interview peer drinking responses 
for ages 12-17 with current peer drinking reported in C-SSAGA assessments, we compared the 
first adult SSAGA response and the maximum value from all C-SSAGA assessments among 
individuals with at least one adult and one child questionnaire. For the 996 participants with both 
adult and child interviews, 73% of peer drinking assignments had the same dichotomous variable 
(none/few vs most/all best friends). This concordance demonstrates that our retrospective 
approach of using the first SSAGA interview when available is a reasonable strategy to assess 
peer drinking across adolescence.  It also shows that for the 12% of participants without a single 
adult SSAGA assessment, using the maximum value from C-SSAGA assessments reasonably 
estimates the proportion of best friends drinking from ages 12-17.  
 
Genotyping 
Blood samples were obtained for genetic analysis. The ADH1B rs1229984 variant was 
genotyped with Sequenom MassArray technology (Sequenom, San Diego, CA, USA) following 
standard procedures. Several quality control measures were employed. Genetic variants had a 
genotyping rate of greater than 99% and were in Hardy-Weinberg equilibrium in both the 
European and African American groups. The program PEDCHECK (O'Connell and Weeks, 
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1998) was used to examine Mendelian inheritance, and only individuals with no Mendelian 
inconsistencies were included in the rs1229984 genotyped sample (N=2580, Figure 3.1). 
A set of 64 ancestry informative markers was genotyped as part of a 96 SNP 
Biorepository Panel by the Rutgers University Cell and DNA Repository. These markers were 
used in SNPrelate, a function in R, to assign ancestry groups. HapMap populations were 
included as reference groups. There was high concordance (97%) between self-reported and 
genetically determined ethnicity for European and African American individuals, and only 
concordant individuals were used in the analyses. 
 
Sample Selection 
In the COGA adolescent and young adult study, 2,580 individuals with a first interview 
age of 12 to 22 were genotyped for the ADH1B rs1229984 variant, and participants for the 
analyses were drawn from this group (Figure 3.1).  Focusing on European and African American 
subjects and excluding individuals with missing or unreliable data left 2,410 individuals (entire 
sample described in Table 3.1). The samples used for the primary analyses of first intoxication 
and first DSM-5 symptom consisted of 1,550 ever-drinkers before age 18 (also described in 
Table 3.1).  Ever-drinkers were targeted because the ADH1B variant is only expected to exhibit 
a protective effect in response to alcohol consumption. Because the peer drinking variable 
examined the age-range of 12-17, the primary analyses focused on events that occurred during 
this time.  
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Data Analysis 
Data were analyzed using the Statistical Analysis System (SAS 9.3, Cary, NC, USA). 
Cox-Proportional Hazards Regression (SAS PROC PHREG) was used to model drinking 
milestones and all individuals who did not experience an event in adolescence were censored at 
their age of last interview or 18. Participants with rs1229984 GA genotype (N=96) and AA 
genotype (N=2) were collapsed into one group for comparison with the GG genotype 
participants (N=1,452), as done in previous studies (Bierut et al., 2012). Models were checked 
for violations of the proportional hazards assumption and Schoenfeld residuals were examined. 
The option COVSANDWICH (AGGREGATE) was used to statistically adjust for the non-
independence of correlated familial data in all analyses, as done in previous studies (Kuperman 
et al., 2013).  
 
Models in Primary Analyses 
Main effects of the ADH1B variant and peer drinking were examined in univariate and 
multivariate models of age of first intoxication and first DSM-5 symptom in the sample of 
adolescent ever-drinkers (N=1,550, called univariate model set and multivariate model set, 
Table 3.2). All models presented in the tables employed STRATA statements for gender and 
ethnicity to adjust for differences in baseline hazards in these groups. The interplay between the 
ADH1B variant and peer drinking was assessed by adding product interaction terms to models of 
drinking milestones (called interaction model set, Table 3.2). This final proportional hazards 
model was λ(t)=λ(t)exp(β1*(rs1229984) + β2*(peer_drinking) + β3*(rs1229984*peer_drinking)). 
The possibility of a gene-environment correlation between ADH1B rs1229984 and peer drinking 
was also assessed because genetic factors influence selection of peers who drink (Fowler et al., 
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2007) and inadequate control of this correlation could produce false interactions. Using logistic 
regression, the outcome peer drinking was modeled with the variables of the ADH1B variant, 
gender, and ethnicity.  
 
Secondary Analyses 
Secondary analyses were performed to test the robustness of our primary findings. First, 
association of the ADH1B rs1229984 variant with the milestone of age of drinking initiation was 
examined in the entire sample, which included adolescent never-drinkers (N=2,410). Second, 
analyses stratified by ancestry were performed to examine the main and interaction effects within 
the subpopulations of European and African Americans.  
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3.4 RESULTS 
 
Participant Characteristics 
Demographic, behavioral, and genotypic characteristics of the study samples are 
presented in Table 3.1. The sample of ever-drinkers before age 18 used in the primary analyses 
consisted of 1,550 individuals from 1,151 nuclear families (defined by full-siblings) and 645 
extended families. The mean first interview age was 17, 49% were female, and the majority 
came from high-risk families (89%) and were European American (73%). Before age 18, 74% 
had a first intoxication and 44% experienced a first DSM-5 symptom of alcohol use disorder. 
From ages 12 to 17, 39% reported that most or all of their best friends drank alcohol. Consistent 
with the expected population frequencies of the ADH1B variant, 6% carried at least one copy of 
the protective A allele (8% in European Americans and 3% in African Americans).  
 
Effect of Peer Drinking 
Most/all best friends drinking compared to none/few best friends drinking between ages 
12-17 was associated with a main hazardous effect in univariate and multivariate models of early 
drinking behaviors (Table 3.2). In the final interaction model set with GxE product terms, self-
reported peer drinking had a robust effect on first intoxication (Hazards ratio (HR)=1.81, 95% CI 
1.62-2.01) and first DSM-5 symptom (HR=2.17, 95% CI 1.88-2.50).  In secondary analyses 
examining all four responses for best friends drinking (none, few, most, all), an increase in the 
number of best friends drinking was similarly related to the first intoxication (multivariate model 
set with none as the reference; few HR=1.72, 95% CI 1.44-2.05; most HR=2.65, 95% CI 2.20-
3.18; all HR=3.69, 95% CI 2.93-4.64) and first DSM-5 symptom (multivariate model set with 
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none as the reference; few HR=2.43, 95% CI 1.77-3.33; most HR=4.29, 95% CI 3.12-5.92; all 
HR=5.84, 95% CI 4.16-8.21). These results indicate a “dosage effect” where the reported 
proportion of best friends drinking was positively associated with higher risk for developing 
adolescent drinking milestones. 
 
Effect of ADH1B rs1229984 Variant 
During adolescence, presence of the ADH1B variant (GA/AA genotypes) was associated 
with a protective main effect among ever-drinkers for first intoxication and first DSM-5 
symptom in univariate and multivariate models (Table 3.2). In the final interaction model set 
with GxE product terms, the effect of the ADH1B variant was strong for both first intoxication 
(HR=0.56, 95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.26-0.77). In 
secondary analyses of the entire sample that included never-drinkers, presence of the variant 
exhibited no effect on drinking initiation (HR in univariate model=1.12, 95% CI 0.92-1.36), 
consistent with the mechanism of the variant of only exhibiting an effect in response to alcohol 
consumption. 
 
Interaction between ADH1B rs1229984 and Peer Drinking 
The interaction between the ADH1B variant and peer drinking was tested by adding GxE 
product term to models of drinking milestones in adolescent drinkers (N=1,550), which 
illustrated a significant statistical interaction for first intoxication (p=.002) and first DSM-5 
symptom (p=.01) (Table 3.2). Among individuals who reported none/few best friends drinking, 
the ADH1B GA/AA genotypes had a strong protective effect for first intoxication (HR=0.56, 
95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.26-0.77). In individuals who 
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reported most/all best friends drinking, however, this protective effect was not observed for 
either first intoxication (HR=1.16, 95% CI 0.82-1.65) or first DSM-5 symptom (HR=1.03, 95% 
CI 0.73-1.45), as illustrated by the point estimates close to 1. Figure 3.2 more clearly illustrates 
this GxE interaction by presenting the survival estimates.  
 
Association between ADH1B Variant and Peer Drinking 
 No evidence of a gene-environment correlation between the ADH1B variant and peer 
drinking was observed. Specifically, the independent variable of the ADH1B rs1229984 variant 
was not significant in the logistic regression model of perceived peer drinking controlling for sex 
and ethnicity as covariates (most/all vs none/few best friends drink, Odds Ratio=1.19, 95% CI 
0.78-1.83).   
 
Assessment of Robustness of Results 
The proportional hazards assumption was satisfied in first DSM-5 symptom models. 
Violations were noted in a subset of first intoxication analyses. Examination of Scholenfeld 
residuals indicated that the group of 17 year olds was driving this violation, perhaps reflecting 
important transitions at this age. Censoring at age 17 instead of 18 satisfied the proportional 
hazards assumption without substantially altering the parameter estimates, supporting our 
conclusions. 
Ancestry-stratified analyses demonstrated consistent main and interaction effects in the 
European American subpopulation (N=1,130). In the interaction model set for European 
American individuals, peer drinking had a hazardous effect on first intoxication (HR=1.87, 95% 
1.66-2.11) and first DSM-5 symptom (HR=2.23, 95% CI 1.89-2.63); rs1229984 had a protective 
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effect on first intoxication (HR=0.60, 95% CI 0.44-0.82) and first DSM-5 symptom (HR=0.47, 
95% CI 0.27-0.82); and interaction terms were significant (p<.02).  The ADH1B GA/AA 
genotypes were protective among individuals reporting none/few best friends drinking, but not 
among those reporting most/all best friends drinking, corroborating our findings in the overall 
sample. 
Stratified analyses of African Americans (N=420) provided trending evidence of main 
effects. In the interaction model set with GxE product terms, peer drinking had a hazardous 
effect on first intoxication (HR=1.62, 95% 1.27-2.08) and first DSM-5 symptom (HR=1.98, 95% 
CI 1.50-2.61); rs1229984 had a trending protective effect on first intoxication (HR=0.32, 95% CI 
0.08-1.27) and first DSM-5 symptom (HR=0.35, 95% CI 0.05-2.28); and interaction terms were 
insignificant (p>.7). The limited sample size of African Americans combined with the low 
frequency of the rs1229984 minor allele limits power to detect interactions in this analysis. 
Nonetheless, the robust effect of peer drinking in both ancestry groups and the well-established 
role of rs1229984 across ancestry groups lends support for our conclusions drawn from the 
combined sample.  
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3.5 DISCUSSION 
 
Alcohol use behaviors established during adolescence are important contributing factors 
for the later progression to alcohol dependence (Grant et al., 2006; Pitkanen et al., 2005). These 
data provide an example of the important interplay of genetic and environmental risks in the 
development of drinking milestones during this critical period of adolescence. Using a 
longitudinal sample of European and African American adolescent drinkers, we demonstrate that 
the ADH1B rs1229984 minor A allele is associated with a protective effect for early drinking 
behaviors, and in the environmental high-risk context of most or all best friends drinking, this 
genetic protection is negated. 
The observation that the ADH1B variant is associated with a decreased risk of first 
intoxication and first DSM-5 symptom during adolescence (Table 3.2) extends previous findings 
that this variant protects against alcohol-related health problems in adulthood ( Bierut et al., 
2012; Gelernter et al., 2014; Li et al., 2011). Despite having an early role in the trajectory of 
drinking behaviors, the ADH1B variant was not associated with drinking initiation, consistent 
with the hypothesized mechanism of action that requires alcohol exposure (Edenberg and 
Foroud, 2013; Hurley and Edenberg, 2012).  This specific example of a genetic variant that 
influences early drinking milestones, but not initiation, builds on twin and adoption study 
findings that genetic factors contribute to the development of adolescent alcohol-related 
problems, and environmental factors more strongly drive drinking initiation (Hopfer et al., 2003; 
Lynskey et al., 2010). 
Beyond demonstrating an early protective role of the ADH1B GA/AA genotypes in the 
development of these drinking behaviors, the results illustrate that reporting most or all best 
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friends drinking was associated with attenuation of this genetic protection (Figure 3.2). The 
observation that social context modifies the effect of an ADH1B variant extends previous studies 
on alcohol metabolizing variants. Higuchi et al. (1994) found that the proportion of alcohol 
dependent adults in Japan with one copy of a protective aldehyde dehydrogenase 2 (ALDH2) 
variant increased between 1979 and 1992, following the increased cultural pressure to drink 
alcohol. Similarly, Irons et al. (2007) reported that the high-risk environment of sibling substance 
use was associated with a diminished effect of this ALDH2 variant in East Asian adolescent 
adoptees, and more recently, this group demonstrated that high parental alcohol use and misuse 
reduced the effect of the ALDH2 protective allele (Irons et al., 2012). For the ADH1B rs1229984 
variant, Hasin et al. (2002) observed a weaker protective role in certain groups, which was 
hypothesized to reflect differences in environmental exposure to heavy drinking. Our findings 
expand on these earlier observations by demonstrating that the critical high-risk social context of 
adolescent peer drinking is associated with the loss of the protective genetic effect of the ADH1B 
variant in European and African Americans. 
Previous studies of metabolizing variants have focused on Asian populations where the 
ADH1B rs1229984 A allele is common, and only recently was this variant associated with 
alcoholism at a genome-wide level in an European and African American sample (p=6.6x10-10) 
(Bierut et al., 2012).  A recent GWAS of alcohol dependence further supports a strong effect of 
this variant in European Americans (p=1.17x10-31) (Gelernter et al., 2014). To our knowledge, 
this study is the first to examine the effect of the ADH1B rs1229984 variant on adolescent 
drinking behaviors and incorporate environmental moderation in European and African 
Americans.  
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One challenge of studying the influence of the ADH1B rs1229984 variant in populations 
of European and African ancestry is the low frequency of the protective A allele. Although over 
1,500 adolescent drinkers were examined in this analysis, only 98 (6%) carried an A allele (of 
which 36 reported most/all best friends drinking). Nonetheless, the influence of this variant and 
the GxE interaction was persistently strong in models of first intoxication and first DSM-5 
symptom (Table 3.2). Secondary ancestry-stratified analyses also demonstrated consistent main 
and interaction effects in the European American subpopulation (N=1,130) and provided 
trending evidence of main effects in the African American subpopulation (N=420), where power 
was limited. These analyses, combined with previous studies supporting the protective role of 
rs1229984 across ancestry groups as well as the moderating effect of social environments, 
support our conclusion that this variant is associated with a protective effect for early drinking 
behaviors in European and African Americans, but this genetic protection may be eliminated by 
adolescent peer drinking. 
 The findings reported here have several limitations. First, studying a specific genetic 
variant provides limited information on the general genetic underpinnings of complex diseases 
such as alcohol use disorder (Dick and Kendler, 2012). Nevertheless, examination of specific 
robust variants provides important insight into underlying biological mechanisms that are not 
assessed by traditional studies of latent genetic influences. Second, other genetic variants may 
influence associations between ADH1B rs1229984 and drinking behaviors (Meyers et al., 2013; 
Toth et al., 2011). Third, self-reported peer drinking was viewed as an environmental risk factor 
in this study, but research suggests that genetic factors contribute to peer alcohol involvement 
(Fowler et al., 2007). Gene-environment correlations can arise when an individual’s heritable 
behavior evokes an environmental response (evocative rGE) or when an individual possesses a 
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heritable propensity to select an environment (active rGE). In this study, the ADH1B rs1229984 
variant was not associated with self-reported peer drinking, supporting our interpretation that 
peer drinking acts as an environmental modifier, but other gene-environment correlations may 
still contribute to the observed effects. Fourth, the temporal ordering of peer drinking and the 
onset of drinking behaviors could not be assessed in this study (Table 3.1).  It is possible that 
other risk factors correlated with peer drinking, such as parental monitoring or genetic risk for 
anti-social behavior, may account for the observed associations. Fifth, peer drinking was 
assessed by respondent report and may not reflect the actual proportion of best friends drinking. 
Finally, the majority of participants were from high-risk families, which may limit the 
generalizability of the findings. It is possible that only individuals at high-risk for alcohol use 
disorders lose the protective effect of the ADH1B rs1229984 variant under environments that 
encourage drinking. Replication of these findings in independent samples is a critical next step. 
Despite these limitations, this study has several strengths. First, the analysis focused on a 
genetic variant with strong statistical and biological evidence for alcohol-related measures, 
which addresses common criticisms of GxE studies (Duncan and Keller, 2011; Joober et al., 
2007; Risch et al., 2009). Second, focusing on a youth population and employing a longitudinal 
study design reduced recall bias, enabling more accurate assessment of drinking behaviors 
during the critical period of adolescence. Third, the robust environment of respondent report of 
best friends drinking from ages 12-17 coincided with the timing of the primary outcomes under 
study. This analysis focused on drinking behaviors that are common in adolescence and therefore 
are more likely to be directly influenced by peer drinking during this period. Finally, studying 
adolescent drinking milestones facilitated the characterization of the unfolding of genetic and 
environmental risks across development. Recent studies further support the discovery potential 
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of examining genetic variants during important behavioral transitions in at-risk youth (Belsky et 
al., 2013; Dick et al., 2013). Future research on alcohol use disorders may benefit from similar 
hypothesis-driven study designs that examine well-established genes and environments during 
critical developmental periods. 
From a public health perspective, this study provides a genetic argument in support of 
early social interventions to decrease affiliation with peer drinkers. Specifically, these findings 
support the use of a screening tool for practitioners to identify at-risk youth, developed by the 
National Institute on Alcohol Abuse and Alcoholism and the American Academy of Pediatrics, 
in which the first question addresses friends’ drinking (NIAAA, 2011).  Under the high-risk 
environment of best friends drinking, all adolescents were at increased risk for early drinking 
problems, and particularly, those at lower genetic risk experienced the greatest added risk. This 
study serves as a model of how understanding the interplay between genes and environments 
may increase etiological knowledge of alcohol use disorders and potentially inform interventions 
that aim to disrupt progression to alcoholism. 
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3.8 TABLES 
Table 3.1. Characteristics of samples used in analyses 
Characteristic Entire sample (N=2,410) Ever-drinkers before age 18 
(N=1,550) 
Ancestry, N (%)   
   European 1,648 (68.4) 1,130 (72.9) 
   African 762 (31.6) 420 (27.1) 
Sex, N (%)    
    Males 1,182 (49.1) 784 (50.6) 
    Females 1,228 (51.0) 766 (49.4) 
Age at first interview, years    
    Mean ± sd 16.3 ± 3.2 16.7 ± 3.0 
    Range 12-22 12-22 
No. of interviews    
    Mean ± sd 3.2 ± 1.1 3.2 ± 1.1 
    Range (1-5) (1-5) 
Family status, N (%)    
    From high-risk families 2,096 (87.0) 1,384 (89.3) 
    From comparison families 314 (13.0) 166 (10.7) 
No. of extended families 781 645 
No. of nuclear families   
   Only full-siblings 1,629 1,151 
   Including half-siblings 1,438 1,044 
No. of individuals per extended  family, 
median (range) 2 (1-24) 2 (1-17) 
Drinking milestones reached before age 18, 
N (%)    
   First drink 1,573 (65.3) 1,550 (100.0) 
   First intoxication 1,170 (48.6) 1,147 (74.0) 
   First DSM-5 symptom 702 (29.1) 683 (44.1) 
Among those who exhibit a first intoxication 
before age 18   
   Mean age ± sd 15.3 (1.5) 15.4 (1.4) 
   Age range 8-17 12-17 
Among those who exhibit a first DSM-5 
symptom before age 18   
   Mean age ± sd 15.6 (1.3) 15.6 (1.2) 
   Age range 10-17 12-17 
rs1229984, N (%)    
    GG 2,270 (94.2) 1,452 (93.7) 
    GA 137 (5.7) 96 (6.2) 
    AA 3 (0.1) 2 (0.1) 
Reported proportion of best friends who use 
alcohol between ages 12-17, N (%)    
    None 746 (31.0) 239 (15.4) 
    Few 981 (40.7) 708 (45.7) 
    Most 513 (21.3) 453 (29.2) 
    All 170 (7.1) 150 (9.7) 
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Table 3.2. Cox proportional hazards regression models of adolescent drinking milestones 
  
Drinking milestones in ever-drinkers before age 18 (N=1,550) 
 
  Models of first intoxication Models of first DSM-5 symptom 
 Hazard ratio  
(95% CI) 
χ2 p 
value 
Hazard ratio  
(95% CI) 
χ2 p 
value 
Univariate model set     
   rs1229984a 0.72 (0.56-0.91) .006 0.69 (0.50-0.94) .02 
   peer drinkingb 1.89 (1.70-2.10) <.0001 2.27 (1.98-2.60) <.0001 
Multivariate model set         
   rs1229984 0.76 (0.61-0.96) .02 0.73 (0.54-0.97) .03 
   peer drinking 1.88 (1.69-2.09) <.0001 2.26 (1.97-2.60) <.0001 
Interaction model set         
   rs1229984 0.56 (0.41-0.76) .0002 0.45 (0.26-0.77) .004 
   peer drinking 1.81 (1.62-2.01) <.0001 2.17 (1.88-2.50) <.0001 
   rs1229984*peer drinking 2.10 (1.32-3.32) .002 2.29 (1.21-4.30) .01 
Examination of GxE term in interaction model 
set 
        
   None/few best friends drink (GA/AA vs GG) 0.56 (0.41-0.76) .0002 0.45 (0.26-0.77) .004 
   Most/all best friends drink (GA/AA vs GG) 1.16 (0.82-1.65) .39 1.03 (0.73-1.45) .87 
 
a Reference ADH1B rs1229984 genotype GG was compared to GA/AA; b Reference peer 
drinking status none/few best friends drink was compared to most/all best friends drink; All 
models adjusted for gender and ethnicity. 
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3.9 FIGURES 
 
Figure 3.1. Sample selection for study analyses. European and African American adolescent 
ever-drinkers with ADH1B rs1229984 genotyping were drawn from the Collaborative Study on 
the Genetics of Alcoholism (COGA) for the primary analyses of two early drinking milestones.  
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Figure 3.2. Survival estimates of drinking milestones stratified by ADH1B rs1229984 genotype 
and perceived best friends drinking. Cox proportional hazards regression survival estimates of (A) first 
intoxication and (B) first DSM-5 alcohol use disorder symptom in adolescent ever-drinkers (N=1,550) 
with the variables of ADH1B genotype, best friends drinking, and GXE interaction term. 
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CHAPTER FOUR: 
CYP2A6 metabolism in the development of nicotine dependence in young adults 
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4.1 ABSTRACT 
 
The gene CYP2A6 encodes the enzyme responsible for the majority of nicotine metabolism. 
Previous studies support that slow metabolizers smoke fewer cigarettes once nicotine dependent, 
but provide conflicting results on the role of CYP2A6 in the development of dependence. By 
focusing on the critical developmental period of young adulthood, this study examines the role of 
variation in CYP2A6 on different smoking milestones. A total of 1,102 European Americans with 
a last interview age from 19-30 years enrolled in the Collaborative Study on the Genetics of 
Alcoholism were genotyped for CYP2A6 variants to calculate a previously well-validated 
nicotine metabolism metric. This metric was not associated with smoking initiation or the 
development of daily smoking (p>0.5), but among daily smokers (n=468), decreased metabolism 
was associated with increased risk of nicotine dependence (defined as Fagerstrom Test for 
Nicotine Dependence score ≥4) after controlling for sex, study site, age of last interview, and 
familial relatedness (p=0.03). This finding was replicated in 335 daily smokers ages 25-30 years 
enrolled in the Collaborative Study of Nicotine Dependence (p=0.02). Meta-analysis indicated 
that slow metabolizers (defined by a metric≤0.85) had a 1.64 increased odds (95% CI 1.17-2.28, 
p=0.004) of developing nicotine dependence as compared to normal metabolizers (metric>0.85). 
Overall, these findings add important knowledge about the complex role of CYP2A6 variation 
across different developmental stages of smoking behaviors. Although slow metabolism may be 
protective for cigarette consumption among nicotine dependent adults, we show that slow 
metabolism is associated with an increased risk of developing nicotine dependence in young 
adult daily smokers.  
85 
 
4.2 INTRODUCTION 
 
The development of nicotine dependence requires smoking initiation, conversion from 
experimental to daily use, and finally the development of advanced smoking behaviors (Belsky 
et al., 2013; Bierut, 2011). Although the majority of adult smokers initiate smoking during 
adolescence, rates of daily smoking substantially increase during young adulthood among ever-
smokers (22% at ages 12-17, 52% at ages 18-34, 62% at ages 35 or more) (NSDUH, 2012). 
Furthermore, among those who report smoking within the past 30 days, the proportion of 
individuals that smoke more than approximately a pack a day also dramatically increases with 
age (6% at ages 12-17, 23% at ages 18-34, and 44% at ages 35 or more) (NSDUH, 2012). 
Increasing our knowledge of what factors drive some young adults and not others to transition 
from initiation to daily smoking and then later smoking behaviors is important for effectively 
preventing the progression of nicotine dependence.  
One genetic factor that may play an important role in the development of smoking 
behaviors is variation in the gene CYP2A6, which encodes a cytochrome P450 enzyme. This 
enzyme is responsible for the majority of oxidation of nicotine to cotinine, which is the primary 
pathway of nicotine metabolism in humans (Hukkanen et al., 2005). The CYP2A6 locus is highly 
polymorphic, and alleles with reduced function have been associated with slower rates of 
nicotine metabolism. Common variants define multiple CYP2A6 haplotypes in European 
ancestry individuals (Haberl et al., 2005), and the majority of inter-individual variation in the 
metabolism of nicotine to cotinine is explained by targeted polymorphisms in European 
Americans (Bloom et al., 2011). 
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 In adults, the region on chromosome 19 encompassing CYP2A6 is genome-wide 
significant in large meta-analyses focused on cigarettes per day in European ancestry populations 
(TAG, 2010; Thorgeirsson et al., 2010). Among nicotine dependent adults, the majority of 
studies demonstrate that genetically slower metabolizers smoke fewer cigarettes per day. This 
observation is thought to reflect the fact that smokers naturally titrate their cigarette consumption 
to maintain steady nicotine levels.  
 Studies in youth present conflicting results on the effect of nicotine metabolism on the 
development of nicotine dependence and other smoking behaviors (Audrain-McGovern et al., 
2007; Huang et al., 2005; Moolchan et al., 2009; O'Loughlin et al., 2004; Rubinstein et al., 2008; 
Rubinstein et al., 2013). Some studies suggest that slow nicotine metabolism is associated with 
an increased risk for acquisition of nicotine dependence (O'Loughlin et al., 2004; Rubinstein et 
al., 2013), possibly reflecting an increased sensitivity to initial nicotine exposure among youth 
that metabolize nicotine more slowly. In contrast, other studies suggest that slower metabolizers 
have a decreased risk for dependence and related symptoms (Audrain-McGovern et al., 2007; 
Rubinstein et al., 2008), paralleling findings in adults regarding heaviness of smoking.  
Our goal was to investigate how variation in CYP2A6 influences the development of 
nicotine dependence and other smoking behaviors during the critical period of young adulthood 
in European Americans. A better understanding of how variation in nicotine metabolism 
contributes to the acquisition of smoking milestones will add to our fundamental knowledge of 
the developmental processes that lead to nicotine dependence and has the potential to identify 
individuals at increased susceptibility during this critical period. 
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4.3 MATERIALS AND METHODS 
 
Primary Sample Description 
The Collaborative Study on the Genetics of Alcoholism (COGA) is a United States multi-
center, family study that aims to identify genes that contribute to alcohol use disorders and 
related phenotypes (Begleiter et al., 1995). Since 2005, the adolescent and young adult study in 
COGA has used a longitudinal design to examine the development of substance use disorders in 
youth from high-risk (defined as recruited through alcohol dependent probands with two or more 
dependent first degree relatives) and community comparison families. Members aged 12 to 22 
were recruited from six sites across the US and interviewed every two years.  
 
Smoking Behaviors in COGA 
Interview assessments were performed using the Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA), which comprehensively gathers detailed information on 
substance use with high reliability and validity (Bucholz et al., 1994; Bucholz et al., 1995; 
Hesselbrock et al., 1999). Smoking initiation was evaluated with the question “Have you ever 
smoked a full cigarette?” Daily smoking, defined as smoking at least 4 days per week for at least 
a month, was assessed among individuals who had initiated smoking using the questions “How 
many cigarettes did you usually smoke a day” and “For how long, did you smoke this many 
cigarettes at that rate?”  
Among individuals who reported daily smoking, several measures of late smoking 
behaviors were assessed that focused on the period of heaviest smoking. Time to first cigarette 
after waking was derived from the question “During this period when you were smoking the 
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most, about how many minutes after you woke up did you smoke your first cigarette?” and the 4 
answers: more than one hour, 31-60 minutes, 6-30 minutes, and within 5 minutes. For the 
primary analyses, time to first cigarette was dichotomized into >5 minutes and ≤5 minutes after 
waking. Cigarettes per day was evaluated with the question “During the period of time when you 
were smoking the most, about how many cigarettes did you usually have per day?” and the 4 
answers: 10 or fewer, 11-20, 21-30, and 31 or more cigarettes. Cigarettes per day was 
dichotomized into ≤20 and >20 cigarettes in the primary analyses as done in previous studies 
(Belsky et al., 2013). A total Fagerstrom Test for Nicotine Dependence (FTND) score during the 
heaviest period of smoking was calculated at each interview using responses to these 2 questions 
as well as responses to questions assessing the four remaining criteria (details in Heatherton et 
al., 1991). For the primary analyses, nicotine dependence was defined as a FTND score of 4 or 
more.  
Given the longitudinal design of this study, an endorsement of smoking initiation or daily 
smoking at any interview was used to capture these behaviors. The highest FTND score across 
available interviews was chosen to capture the lifetime maximum, and the variables time to first 
cigarette as well as cigarettes per day were set at these same interviews.  
 
Genotyping 
 Recently, Bloom et al. (2011) developed a metric based on several genetic variants in 
CYP2A6 to estimate nicotine metabolism. Cross-validation estimates that this metric predicts 
approximately 70% of the variance in metabolism of orally administered nicotine to cotinine in 
European Americans. Our goal was to use this CYP2A6 metabolism metric to test whether 
CYP2A6 variation predicts cigarette smoking behaviors.  
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Blood samples from COGA were obtained for genetic analysis. Five CYP2A6 single 
nucleotide polymorphisms (SNPs) (rs1801272, rs28399442, rs28399433, rs1137115, 
rs28399435) were genotyped using the LGC Genomics Competitive Allele-Specific PCR 
(KASP), a FRET-based endpoint genotyping assay (http://www.lgcgenomics.com). PCR 
reactions were run on an ABI GeneAmp PCR System 9700, and fluorescence measurements 
taken on an ABI 7900HT Fast Real-Time PCR System (http://www.lifetechnologies.com). The 
CYP2A6 copy number variant (CNV) was genotyped with TaqMan 5’ Nuclease Assays 
(Hs00010002_cn and Hs07545275_cn, Life Technologies) using a standard qPCR protocol on 
the ABI 7900HT System. The CNV assay was run in duplicate, and genotype calls were made 
using CopyCaller software. The program PEDCHECK (O'Connell and Weeks, 1998) was used 
to examine Mendelian inheritance, and only individuals with no Mendelian inconsistencies were 
included in the genotyped sample. The metabolism metric was calculated based on the genotypes 
of the five CYP2A6 SNPs and the CNV using an algorithm described in Supplemental Table 4.1 
(adapted from Bloom et al., 2012).  
 A set of 64 ancestry informative markers was genotyped as part of a 96 SNP 
Biorepository Panel by the Rutgers University Cell and DNA Repository. These markers were 
used in SNPrelate, a function in R, to assign ancestry groups. HapMap populations were 
included as reference groups. There was high concordance (98%) between self-reported and 
genetically determined ethnicity among European Americans. Only genetically determined 
European Americans were included in the analysis because the metric was optimized for this 
population (Bloom et al., 2011). 
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Primary Sample Selection 
 In the COGA adolescent and young adult study, 1,102 European ancestry individuals 
with age of last interview between 19 and 30 were genotyped for the CYP2A6 variants, and 
participants for the analyses were drawn from this group (Figure 1).  The analysis was restricted 
to individuals who had reached young adulthood because we were interested in transitions to 
daily smoking and late smoking behaviors, outcomes that often occur during this time. The 
sample used to analyze daily versus non-daily smokers consisted of 706 (64%) individuals who 
had initiated smoking. For transitions to late smoking behaviors, we focused on the sample of 
468 (66%) daily smokers (described in Table 4.1).  
 
Replication COGEND sample  
 The Collaborative Study of Nicotine Dependence (COGEND) is a multi-center case-
control study designed to identify genes that contribute to nicotine dependence (Saccone et al., 
2007). Community based recruitment enrolled participants ages 25-45 years old. Cases were 
required to be current smokers and have an FTND score of 4 or more. Controls were required to 
have smoked at least 100 cigarettes and have a lifetime maximum FTND score of 1. For this 
analysis, only subjects who self-identified as being of European ancestry were examined, and 
previous analyses using EIGENSTRAT have shown a high correspondence with genetically 
determined ancestry groups (Saccone et al., 2009). Genotyping of variants to calculate the 
metabolism metric in COGEND has been previously described (Bloom et al., 2012). We focused 
on the subsample of 377 COGEND young adults ages 25-30, which overlapped with the age 
range of the COGA young adult sample. From this group, 335 (89%) reported smoking every 
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day or nearly every day for at least 2 months and were considered daily smokers. Replication 
sample characteristics of these daily smokers are described in Table 4.1.  
 
Primary Data Analysis 
Data were analyzed using the Statistical Analysis System. Logistic regression was used to 
model dichotomous outcomes of daily smoking, nicotine dependence, time to first cigarette, and 
cigarettes per day. In the primary analyses in COGA and COGEND, the continuous metabolism 
metric, sex, study site, and last interview age were included as variables. In COGA, family 
structure was accounted for using generalized estimating equations via PROC GENMOD. 
Results from the COGEND replication sample were meta-analyzed with the primary COGA 
results (Table 4.2) using a publically available SAS macro 
(http://www.hsph.harvard.edu/spiegelman/metaanal.html). Meta-analyses results were based on 
fixed effect models to determine the evidence for association within the collected samples. In 
these analyses, we did not observe heterogeneity between the two studies based on the Q statistic 
(p>0.1). 
 
Secondary Data Analyses 
Several secondary analyses were performed to test the robustness of our primary 
findings. First, individuals were divided into slow and normal metabolizers using a cut-off of 
≤0.85 on the metabolism metric as done in previous studies (Chen et al., 2014). This cut-off 
represents approximately the lowest quartile of metabolizers and this dichotomous variable was 
examined in logistic regression models of smoking behaviors. Second, the 4 level variable of 
time to first cigarette after waking (>60, 31-60, 6-30, ≤5 minutes) was also investigated in 
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cumulative logistic regression models to assess whether the metabolism metric predicted 
response across these four ordinal categories. Third, because FTND contains information about 
time to first cigarette, we also examined the equation predicting dichotomous nicotine 
dependence with this added variable of time to first cigarette. Finally, we calculated FTND 
scores without the question regarding time to first cigarette after waking and explored the 
association between the metabolism metric and this new alternative nicotine dependence 
measure.  Without the important question of time to first cigarette after waking, this alternative 
score was ≥4 for only 25% (115/461) of young adult daily smokers in COGA and 26% (87/335) 
in COGEND. 
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4.4 RESULTS 
 
Participant Characteristics 
 Demographic, behavioral, and metabolism metric characteristics of the COGA and 
COGEND samples are presented in Table 4.1. The primary COGA sample of young adult daily 
smokers consisted of 468 European American individuals from 401 nuclear families and 293 
extended families. The mean age at last interview was 24: 44% were female, and the majority 
came from families at high-risk for alcoholism (92%). Among these daily smokers, 59% were 
nicotine dependent, 32% smoked within 5 minutes after waking, and 26% smoked greater than 
20 cigarettes per day (Figure 4.1 and Table 4.2). Twenty-six percent of the young adults were 
slow metabolizers, and the distribution of the metabolism metric (Supplemental Figure 4.1) was 
similar to that seen in other samples (Bloom et al., 2012; Chen et al., 2014).  
The COGEND replication sample of young adult daily smokers consisted of 335 
European Americans with an average age at interview of 28, and the majority were female 
(61%).  Among COGEND young adult daily smokers, 50% were nicotine dependent, 24% 
smoked within 5 minutes after waking, 25% smoked greater than 20 cigarettes per day, and 30% 
were slow metabolizers (distribution in Supplemental Figure 4.1) . 
 
CYP2A6 Metabolism Metric and Early Smoking Behaviors 
The CYP2A6 metabolism metric was not associated with smoking initiation (p=0.51) and 
the development of daily smoking (p=0.57) in the COGA young adults (Table 4.2). Therefore, 
subsequent analyses of late smoking milestones focused on the 468 daily smokers. Of the 238 
young adults who initiated smoking but did not transition to daily smoking, essentially all of 
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them (99.6%) failed to develop any of the late smoking behaviors. This supports the notion that 
daily smoking is a prerequisite for the development of late smoking behaviors. 
 
CYP2A6 Metabolism Metric and Late Smoking Behaviors in Daily Smokers 
CYP2A6 haplotypes predictive of slower metabolism were associated with an increased 
risk of nicotine dependence in both the primary COGA and replication COGEND samples of 
young adult daily smokers (Table 4.2, Figure 4.2). In multivariate models adjusting for age, sex, 
and study site, the continuous CYP2A6 metabolism metric had a significant effect in COGA (p 
=0.03) and COGEND (p=0.02), where a slow predicted metabolism was associated with an 
increased risk of nicotine dependence defined by an FTND score ≥4 (Table 4.2). Secondary 
analyses showed that slow metabolizers (defined by a metric of ≤0.85) had a 1.64 increased odds 
(95% CI 1.17-2.28, p=0.004) of developing nicotine dependence as compared to normal 
metabolizers (metric>0.85) in meta-analyses of COGA and COGEND studies (Supplemental 
Table 4.2). Figure 4.2 illustrates this association by showing that a larger proportion of slow 
metabolizers in both COGA and COGEND developed nicotine dependence as compared to 
normal metabolizers.  
Consistent with the nicotine dependence results, a lower metabolism metric was 
associated with an increased risk of smoking within 5 minutes after waking (Table 4.2, Figure 
4.2). The continuous CYP2A6 metabolism metric had a trending effect in COGA (p=0.07) and a 
significant effect in COGEND (p=0.01). In meta-analysis, slow metabolizers had a 1.61 
increased odds (95% CI 1.15-2.26, p=0.006) of smoking within 5 minutes after waking 
compared to normal metabolizers (Supplemental Table 4.2, Figure 4.2).  The CYP2A6 
metabolism metric was not associated with smoking more than 20 cigarettes per day in both 
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samples (Table 4.2), and Figure 4.2 illustrates that a similar proportion of slow and fast 
metabolizers reported smoking more than 20 cigarettes per day. 
 
Robustness of effect of CYP2A6 Metabolism Metric on Time to First Cigarette after 
Waking 
Examination of all 4 responses of time to first cigarette after waking (≥60, 31-60, 6-30, 
≤5 minutes) in secondary analyses demonstrated a slightly more robust effect of the metabolism 
metric in both COGA (p=0.06) and COGEND (p=0.004) as compared to the dichotomous 
variable of time to first cigarette (>5 and ≤5 minutes) (Supplemental Table 4.3 and Table 4.2, 
respectively).  Supplemental Figure 4.2 illustrates that across the 4 categories, there was an 
increased proportion of slow metabolizers at shorter times to first cigarette after waking among 
COGA daily smokers. In COGEND daily smokers, we observed a similar trend, except in the 
category of 31-60 minutes that only had 19 individuals (6% of sample, Table 4.1). Taken 
together these results support a possible “dosage effect” where predicted slower metabolism was 
correlated with smoking sooner after waking. 
  Since time to first cigarette after waking contributes to the calculation of FTND score, 
we also examined the effect of the metabolism metric on nicotine dependence after controlling 
for time to first cigarette after waking as a variable. In COGEND, the metabolism metric was no 
longer a significant predictor of nicotine dependence (p=0.23) and in COGA the significance was 
diminished (p=0.04) (Supplemental Table 4.4). Furthermore, when FTND scores were 
calculated excluding the time to first cigarette after waking question, there was essentially no 
association between the metabolism metric and this adjusted measure of nicotine dependence 
(COGA p=0.51 and COGEND p=0.69, Supplemental Table 4.4). These results suggest that our 
96 
 
primary association between the CYP2A6 metabolism metric and nicotine dependence is driven 
by time to first cigarette after waking. 
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4.5 DISCUSSION 
 
 Young adulthood is a critical developmental period for the progression from initiation to 
late smoking milestones (NSDUH, 2012). This study links variation in a genome-wide 
significant gene, CYP2A6, with the development of smoking behaviors in two independent 
samples of European American young adults. Using specific CYP2A6 polymorphisms, we 
calculated a nicotine metabolism metric, which has been previously shown to account for 
approximately 70% of the variance in metabolism of orally administered nicotine to cotinine in 
European Americans (Bloom et al., 2012; Bloom et al., 2011). Our primary finding is that 
decreased predicted nicotine metabolism is associated with an elevated risk of developing 
nicotine dependence among young adult daily smokers, adding important insight into the role of 
variation in CYP2A6 across stages of smoking development, as illustrated in Figure 4.3.  
Despite having an important role in the development of nicotine dependence, variation in 
CYP2A6 was not associated with smoking initiation or the progression to daily smoking (step 1 
in Figure 4.3).  Previous twin studies support that environmental influences primarily drive early 
adolescent nicotine use, and that the role of heritable factors on smoking behaviors increases 
throughout young adulthood (Kendler et al., 2008; Koopmans et al., 1999). Our results are 
consistent with this model by providing evidence of a gene that impacts the transition from daily 
smoking to nicotine dependence, without influencing initiation and daily smoking.   
 The observation that decreased predicted nicotine metabolism is associated with 
increased risk of nicotine dependence in young adults also builds on previous studies conducted 
in adolescents (step 2 in Figure 4.3). O’Loughlin et al. (2004) followed 228 non-dependent 
smokers in grade 7 over approximately 30 months and found that those with inactive genetic 
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variants in CYP2A6 were more likely to develop nicotine dependence by the international 
classification of diseases (ICD-10) criteria, but smoked fewer cigarettes per day once dependent. 
Huang et al. (2005) examined variation in CYP2A6 in 1,518 adolescents enrolled in a 
longitudinal study in the United Kingdom and similarly found that individuals with inactive 
variants associated with slower metabolism were more likely to be current versus former 
smokers at age 18 compared to normal metabolizers.  More recently, Rubinstein et al. (2013) 
assessed a biomarker of the rate of nicotine metabolism (the nicotine metabolite ratio) in 164 
adolescent smokers and found that slower metabolizers showed greater symptoms of dependence 
on the modified Fagerstrom Tolerance Questionnaire. Our findings expand on these earlier 
results by demonstrating that during young adulthood, when many late smoking behaviors 
develop, slow metabolizers continue to have a greater risk of dependence.  
The increased susceptibility to developing nicotine dependence encountered by youth 
slow metabolizers has been hypothesized to reflect prolonged exposure to nicotine during initial 
smoking experiences (Chenoweth et al., 2013; Malaiyandi et al., 2005; Rubinstein et al., 2013). 
Although accumulating evidence support this role, it is important to note that a few studies show 
the opposite effect where slow metabolism is associated with decreased risk of smoking 
behaviors in youth (Audrain-McGovern et al., 2007; Moolchan et al., 2009; Rubinstein et al., 
2008). For example, Audrain-McGovern (2007) examined 222 European ancestry adolescent 
ever-smokers and found that normal CYP2A6 metabolizers developed symptoms of dependence 
on the modified Fagerstrom Tolerance Questionnaire at a faster rate than slower CYP2A6 
metabolizers. Many possible explanations exist for these discrepant results, including differences 
in measures of nicotine metabolism and dependence.  
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Our results suggest that time to first cigarette after waking is a critical contributor to the 
association between the CYP2A6 metabolism metric and nicotine dependence assessed by the 
FTND criteria.  Little consensus exists on the best measure of nicotine dependence, but research 
supports that two items from the FTND score, time to first cigarette after waking and cigarettes 
per day, are strong, valid, reliable predictors of quitting behaviors, which are key indicators of 
dependence (Baker et al., 2007; Borland et al., 2010; Hyland et al., 2006). Studies also suggest 
that these two measures are distinct predictors of addiction (Borland et al., 2010; Lessov et al., 
2004), suggesting the possibility that different genetic factors may contribute to urgency to 
smoke and levels of cigarette consumption. In a sample of over 1000 young adults, Haberstick et 
al. (2007) found that time to first cigarette was the most informative measure of heritable factors 
from the FTND score. Our results complement these findings by illustrating that necessity to 
smoke measured by time to first cigarette after waking drives the association of the CYP2A6 
metabolism metric and nicotine dependence in young adults.  
These findings in young adults should be considered in the context of the adult literature. 
Previous studies of adults demonstrate that once dependent, genetically slower metabolizers 
smoke fewer cigarettes to reach target blood nicotine levels (Benowitz, 2008) (step 3 in Figure 
4.3). Although we did not observe an effect of slow metabolism on risk of smoking more than 20 
cigarettes per day among daily smokers (Table 4.2, Figure 4.2), only 26% of these young adults 
were heavy smokers, and heaviness of smoking continues to increase throughout adulthood 
(NSDUH). In the entire COGEND sample ages 25-45, previous work suggests that once 
dependent, slower metabolism is associated with decreased cigarette consumption (Bloom et al., 
2012). These findings underscore that variation in CYP2A6 has a variety of effects on smoking 
behaviors across stages of development in the COGEND sample: slow metabolism leads to 
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increased risk for developing nicotine dependence in young adult daily smokers, but once 
dependent, slow metabolism is protective for heaviness of smoking. 
Another important consideration is that the fraction of slow metabolizers in the 
population of smokers has been observed to decrease with age, suggesting that slow metabolizers 
are more likely to quit smoking (Benowitz, 2008) (step 4 in Figure 4.3). Among COGEND 
dependent current smokers ages 25-30 years, we found that 36% (60/166) were slow 
metabolizers. However, among COGEND current dependent smokers over 30 years old, only 
28% (250/883) were slow metabolizers, supporting that proportionally more slow metabolizers 
have quit by this time.  Furthermore, other studies directly support that slow nicotine 
metabolism, measured by CYP2A6 genotypes or the nicotine metabolite ratio, is associated with 
increased cessation rates in both youth (Chenoweth et al., 2013) and adults enrolled in clinical 
trials (Ray 2009; Chen 2014). Taken together, these findings suggest that across development, 
slow metabolizers may quit smoking more easily. Therefore, the observation that slow 
metabolism is associated with increased risk of nicotine dependence may be most pronounced in 
samples of youth when symptoms of dependence are first developing and before cessation 
attempts occur. 
The findings reported here have limitations. First, this study focused on European 
Ancestry individuals because the metabolism metric was optimized for this population (Bloom et 
al., 2011). Second, the temporal ordering of smoking behaviors could not be examined in this 
analysis because the smoking questions did not assess age of onset in COGA, and COGEND is a 
cross-sectional study. Third, the majority of the COGA participants were from families at high 
risk for alcoholism, which may limit the generalizability of the findings. Replication of the 
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primary findings in a community based recruitment sample (COGEND), however, supports that 
the findings are not specific to a high-risk population. 
In summary, using a validated CYP2A6 metabolism metric, this study demonstrates that 
slower nicotine metabolism is associated with an increased risk of nicotine dependence in two 
independent samples of young adult daily smokers.  These findings add important knowledge 
about the complex role of CYP2A6 variation across different developmental stages of smoking 
stages. From a public health perspective, these findings and others (Belsky et al., 2013) provide a 
genetic argument in support of early interventions before the development of nicotine 
dependence. 
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4.8 TABLES 
Table 4.1. Characteristics of primary and replication samples of European American young 
adults 
Characteristic  COGA Young Adult 
European American 
Daily Smokers (N=468) 
COGEND Young Adult 
European American 
Daily Smokers (N=335) 
Sex, N (%)   
    Males 264 (56%) 129 (39%) 
    Females 204 (44%) 206 (61%) 
Age at last interview, years   
    Mean ± sd 23.6 ± 3.0 27.8 ± 1.7 
    Range 19-30 25-30 
No. of interviews   
    Mean ± sd 3.6 ± 1.2 - 
    Range 1-5 1 
Family status, N (%)   
    From high-risk families 431 (92%) - 
    From comparison families 37 (8%) - 
No. of extended families 293 - 
No. of nuclear families (full siblings) 401 - 
FTND score   
    Mean ± sd 4.1 ± 2.6 3.0 ± 3.3 
    Range 0-10 0-10 
Nicotine dependence (FTND≥4), N (%) 276 (59%) 166 (50%) 
Time to first cigarette after waking   
    More than 1 hour 86 (18%) 168 (50%) 
    31-60 minutes 67 (15%) 19 (6%) 
    6-30 minutes 167 (36%) 67 (20%) 
    Within 5 minutes 148 (32%) 81 (24%) 
Cigarettes per day   
    10 or fewer 171 (37%) 171 (51%) 
    11-20 169 (37%) 78 (23%) 
    21-30 72 (16%) 45 (13%) 
    31 or more 48 (10%) 41 (12%) 
Metabolism metric*   
    Mean ± sd 0.86 ± 0.07 0.86 ± 0.07 
    Range 0.44-0.90 0.44-0.90 
Metabolism status   
    Low (Metric ≤ .85) 123 (26%) 103 (31%) 
    Normal (Metric > .85) 345 (74%) 232 (69%) 
 
*Distribution of metabolism metric in COGA and COGEND young adult daily smokers provided 
in Supplemental Figure 4.1.  
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Table 4.2. Logistic regression models of smoking milestones in young adults 
 
 Metabolism Metric in 
COGA Young Adults 
 
Metabolism Metric in  
COGEND Yong Adults 
Meta-analysis of results 
 Estimate SE p-value Estimate SE p-value Estimate SE p-value 
Among all young adults (COGA n=1,102)          
   Smoking initiation 0.67 1.03 0.51 - - - - - - 
Among young adult ever-smokers (COGA 
n=706) 
         
   Daily smoking -0.68 1.22 0.57 - - - - - - 
Among young adult daily smokers  
(COGA n=468; COGEND n=335) 
         
   Nicotine dependence 3.94 1.76 0.03 4.36 1.86 0.02 4.14 1.28 0.001 
   Smoked within 5 minutes after waking 2.44 1.35 0.07 4.63 1.82 0.01 3.22 1.09 0.003 
   Smoked 20 cigarettes per day -0.58 1.49 0.70 1.53 1.85 0.41 0.25 1.16 0.83 
 
All models include sex, study site, and age of last interview as covariates; Analyses with COGA 
were also adjusted for familial clustering; 
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4.9 FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Primary COGA sample selection 
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Figure 4.2. Association between predicted metabolism and smoking behaviors in two studies of 
European American young adult daily smokers. Error bars reflect standard errors. 
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Figure 4.3.  A theoretical framework of the development of smoking behaviors in relation to 
CYP2A6 variation 
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4.10 SUPPLEMENTAL TABLES 
Supplemental Table 4.1. Predicted metabolism metric and CYP2A6 diplotypes based on copy 
number and 5 SNPs  
CYP2A6 
Copy 
number 
rs1801272+ 
rs28399442 rs28399433 rs1137115 rs8399435 Haplotype 1 Haplotype 2 
Predicted 
Metabolism 
metric 
0  *4 *4 0.44 
1 
≥1  *4 *2/*12 0.44 
0 
≥1  *4 *9 0.64 
0 
≥1 
0 *4 *1A 0.68 
≥1 *4 other 0.76 
0  *4 other 0.76 
≥2 
2  *2/*12 *2/*12 0.44 
1 
≥1  *2/*12 *9 0.64 
0 
≥1 
0 *2/*12 *1A 0.68 
≥1 *2/*12 other 0.76 
0  *2/*12 other 0.76 
0 
2  *9 *9 0.76 
1 
1 
0 *9 *1A 0.79 
1 *9 other 0.85 
0  *9 other 0.85 
0 
2 
0 *1A *1A 0.82 
1 *1A other 0.87 
2 other other 0.90 
1 
0 *1A other 0.87 
1 other other 0.90 
0  other other 0.90 
 
Adapted from Bloom et al. 2012;  
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Supplemental Table 4.2. Examination of dichotomous metabolism status as a predictor of 
smoking milestones in logistic regression models in young adults 
  Metabolizer status in 
COGA Young Adults 
 
Metabolizer status in  
COGEND Young 
Adults  
Meta-analysis of 
results 
 Odds Ratio  
(95% CI) 
p value Odds ratio  
(95% CI) 
p 
value 
Odds ratio  
(95% CI) 
p value 
Among all young adults (COGA 
n=1,102) 
      
   Smoking initiation 0.97  
(0.72-1.30) 
0.82 - - - - 
Among young adults ever-smokers 
(COGA n=706) 
      
   Daily smoking 0.78  
(0.54-1.04) 
0.18 - - - - 
Among young adults who smoked daily  
(COGA n=468; COGEND n=335) 
      
   Nicotine dependence 1.51  
(0.96-2.38) 
0.08 1.79 
 (1.10-2.91) 
0.02 1.64  
(1.17-2.28) 
0.004 
   Smoke within 5 minutes 1.44  
(0.93-2.23) 
0.10 1.89  
(1.11-3.22) 
0.01 1.61  
(1.15-2.26) 
0.006 
   Smoke greater than 20 0.98  
(0.62-1.56) 
0.94 1.13  
(0.76-2.29) 
0.67 1.04  
(0.73-1.48) 
0.82 
 
All models include sex, study site, and age of last interview as covariates; Analyses with COGA 
were adjusted for familial clustering. 
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Supplemental Table 4.3. Logistic regression models of the ordinal 4 level variable of time to 
first cigarette after waking (>60, 31-60, 6-30, ≤5 minutes) 
 
 Metabolism Metric in 
COGA Young Adult 
Daily smokers (n=468) 
 
Metabolism Metric in  
COGEND Yong Adult Daily 
Smokers (n=335) 
Meta-analysis of results 
of Daily Smokers 
 Beta SE p value Beta SE p value Beta SE p value 
Time to first cigarette after waking 2.43 1.28 0.06 4.55 1.58 0.004 3.27 0.99 0.001 
 
All models include sex, study site, and age of last interview as covariates; Analyses with COGA 
were also adjusted for familial clustering. 
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Supplemental Table 4.4. Logistic regression models of nicotine dependence that explore the 
importance of time to first cigarette after waking 
 Metabolism Metric in 
COGA Young Adult 
Daily smokers (n=468) 
 
Metabolism Metric in  
COGEND Yong Adult Daily 
Smokers (n=335) 
Meta-analysis of results 
of Daily Smokers 
 Beta SE p value Beta SE p value Beta SE p value 
Nicotine dependence conditioned on 
time to first cigarette after waking  5.25 2.54 0.04 -18.66 15.7 0.23 4.63 2.25 0.07 
 
Nicotine dependence based on 
adjusted FTND scores calculated 
without the time to first cigarette 
after waking question 
-1.09 1.65 0.51 0.74 2.86 0.69 -0.28 1.23 0.82 
 
All models include sex, study site, and age of last interview; Analyses with COGA were also 
adjusted for familial clustering; 
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4.11 SUPPLEMENTAL FIGURES 
 
 
 
Supplemental Figure 4.1. Distribution of CYP2A6 metabolism metric among COGA and 
COGEND young adult daily smokers. 
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Supplemental Figure 4.2. Proportion of slow metabolizers among 4 categories of time to first 
cigarette after waking among young adult daily smokers 
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CHAPTER FIVE: 
Common, low frequency, and rare coding variants in CHRNA5 contribute  
to nicotine dependence in European and African Americans 
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5.1 ABSTRACT 
  
The functional nonsynonymous variant rs16969968 in the α5 nicotinic receptor subunit gene 
(CHRNA5) is the strongest genetic risk factor for nicotine dependence in European Americans 
(MAF=0.35), and contributes to risk in African Americans (MAF=0.06). To comprehensively 
examine whether other CHRNA5 coding variation influences nicotine dependence risk, we 
performed targeted sequencing on 1 582 nicotine dependent cases (Fagerstrom Test for Nicotine 
Dependence score≥4) and 1 238 controls ages 25-45, with independent replication of common 
and low frequency variants using 12 studies with exome chip data. Next-generation sequencing 
with 180X coverage identified 24 nonsynonymous variants and 2 frameshift deletions in 
CHRNA5, including 9 novel variants. Nicotine dependence was examined using logistic 
regression and the variables sex, age, ancestry PCs, individual common variants (MAF≥0.05), 
aggregate low frequency variants (0.05>MAF≥0.005), and aggregate rare variants (MAF<0.005). 
Meta-analysis of primary results with replication studies containing 12 174 heavy and 11 290 
light smokers confirmed robust independent risk effects of the only common variant 
(rs16969968, European: OR=1.3, p=3.5x10-11; African: OR=1.3, p=0.01) and 3 low frequency 
variants (aggregate term, European: OR=1.3, p=0.005; African: OR=1.4, p=0.0006). The 
remaining 22 rare coding variants were associated with increased risk in the European American 
primary sample (OR=12.9, p=0.01) and in the risk direction in African Americans (OR=1.5, 
p=0.37). Beyond the well-studied rs16969968, we show that low frequency and rare CHRNA5 
coding variants are independently associated with nicotine dependence risk. These newly 
identified variants may have important health implications by influencing risk for smoking-
related diseases and response to cessation therapies.  
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5.2 INTRODUCTION 
 
Nicotine is the primary addictive component of tobacco products, and its physiological 
effects are mediated largely through neuronal nicotinic acetylcholine receptors (Dani and De 
Biasi, 2001). The α5/α3/β4 nicotinic subunit gene cluster on chromosome 15 harbors the 
strongest and most replicated genetic risk factor for several smoking related traits. Specifically, 
many independent studies demonstrated that rs16969968, a single nucleotide polymorphism in 
the α5 subunit gene (CHRNA5), is associated with nicotine dependence, cigarettes per day, 
smoking cessation, chronic obstructive pulmonary disease, and lung cancer (Amos et al, 2008; 
Berrettini et al, 2008; Bierut et al, 2008; Caporaso et al, 2009; Chen et al, 2012a; Chen et al, 
2009; Hung et al, 2008; Pillai et al, 2009; Saccone et al, 2007; Thorgeirsson et al, 2008). 
Subsequent large-scale meta-analyses of European ancestry populations, where the rs16969968 
minor allele is common (minor allele frequency (MAF)=0.35 in Exome Variant Server), 
identified this region as unequivocally associated with heaviness of smoking (p=5.57x10-72) (Liu 
et al, 2010; TAG, 2010; Thorgeirsson et al, 2010). Recently, rs16969968 was shown to have a 
similar effect in African ancestry populations (Chen et al, 2012b; Saccone et al, 2009), where the 
minor allele is less common (MAF=0.06 in Exome Variant 
Server)(http://evs.gs.washington.edu/EVS/).   
Beyond robust association studies across ancestry groups, functional studies support the 
biological role of CHRNA5 and rs16969968 in the development of nicotine dependence. The 
highest density of α5 subunits has been reported in the interpeduncular nucleus in the brain, 
which receives input from the medial habenula (Hsu et al, 2013; Marks et al, 1992). Fowler et al. 
(2011) demonstrated that mice with a null mutation for Chrna5 exhibited increased nicotine 
124 
 
intake, which was “rescued” by re-expression of α5 in the medial habenula. Their findings 
support the hypothesis that nicotine activates the habenulo-interpeduncular pathway through α5 
containing receptors, limiting further nicotine intake. Genetic alterations that decrease the 
function of α5 would therefore be expected to increase liability towards nicotine dependence. 
Consistent with this hypothesis, the risk allele of rs16969968 has been shown to reduce receptor 
function (Bierut et al, 2008; Kuryatov et al, 2011). Specifically, the A allele of rs16969968 
causes an aspartic acid to asparagine change at position 398 in the α5 subunit, and expression of 
this risk allele leads to decreased response to nicotine agonists in cell culture (Bierut et al, 2008) 
as well as lower Ca2+ permeability and increased short term desensitization when incorporated 
into certain neuronal nicotinic receptors (Kuryatov et al, 2011).  
We hypothesized that additional low frequency and rare α5 coding variants may alter risk 
for nicotine dependence. To comprehensively assess the relationship between CHRNA5 coding 
variation and liability to nicotine dependence, we analyzed targeted sequence data from 
approximately 3 000 nicotine dependent cases and non-dependent controls of European and 
African descent. In addition, we used 12 studies with exome chip data for replication analysis of 
the associations of common and low frequency variants with smoking behaviors found in our 
primary data. 
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5.3 MATERIALS AND METHODS 
 
Primary Sample Ascertainment and Description 
Subjects were recruited from the St Louis MO, Detroit MI, and Chicago IL metropolitan 
areas through the Collaborative Genetic Study of Nicotine Dependence and the Genetic Study of 
Nicotine Dependence in African Americans (Bierut et al, 2007; Saccone et al, 2007). 
Community-based recruitment enrolled subjects aged 25-45 years old. All subjects underwent 
comprehensive phenotypic assessments of smoking behaviors, including the Fagerstrom Test for 
Nicotine Dependence (FTND). Nicotine dependent cases were required to be current smokers 
and have an FTND score of 4 or higher. Non-dependent controls had smoked at least 100 
cigarettes (to ensure exposure to nicotine) but had a lifetime maximum FTND score of 1.  
 
Targeted sequencing of CHRNA5 
DNA samples were derived from blood. The Center for Inherited Disease Research 
(CIDR) performed next-generation targeted sequencing on genes strongly associated with 
smoking, including CHRNA5. Details of the sequencing procedures and quality control measures 
are provided in the Supplemental Methods. The mean on-target coverage was 180X, and 
greater than 96% of on-target bases had a depth greater than 20X.  
 
Evaluation of CHRNA5 coding variants 
Genotypic data that passed initial quality control at CIDR were released to the Quality 
Assurance/Quality Control analysis team at the University of Washington Genetics Coordinating 
Center. CHRNA5 coding variants were identified by ANNOVAR (Wang et al, 2010) and then 
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manually reviewed. This review involved examining summary statistics of the quality control 
metrics, comparing the quality of novel variants with known variants from dbSNP and HapMap, 
as well as inspecting alignments of selected samples with non-reference calls to pass or fail 
variant sites. Seven samples were identified as low quality and omitted. Large genetic databases 
(Abecasis et al, 2012) and protein prediction programs (Gonzalez-Perez and Lopez-Bigas, 2011) 
were also used to assess identified coding variants. 
Previously, Haller et al (2012) performed pooled sequencing of CHRNA5 in a sample that 
also contributed 511 participants to targeted sequencing, identifying 4 CHRNA5 coding variants 
beyond the well-studied rs16969968. Targeted sequencing found these 4 coding variants in the 
same 34 people as pooled sequencing, demonstrating high concordance. Furthermore, targeted 
sequencing also identified 6 additional singleton variants among the 511 people included in both 
analyses. The high quality of the targeted sequencing data was further verified using the 
HumanExome-12v1-1 array. All 2 820 individuals included in our primary analysis were 
genotyped using this array, and the concordance for the common and low frequency coding 
variants was 99.9%. 
 
Data Analysis 
A total of 1 432 European and 1 388 African Americans with targeted sequencing of 
CHRNA5 and available smoking behaviors were examined in this analysis. Data were analyzed 
using the Statistical Analysis System (SAS 9.3, Cary, NC, USA). Logistic regression was used to 
model case-control status. European and African Americans were analyzed separately. Ancestry 
groups were verified using EIGENSTRAT (Price et al, 2006) and previously collected genome-
wide arrays. HapMap populations were included as reference groups and linkage disequilibrium 
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filters were applied. Ten ancestry-specific principal components (PCs) were also developed. 
Examination of eigenvalues led us to include the first PC in our statistical analyses of both 
ancestry groups. All models included the standard covariates of sex, age, and first ancestry-
specific PC.  
We analyzed all variants identified by ANNOVAR as functional. These coding variants 
were divided into three classes based on the derived MAF in the entire sample: rare 
(MAF<0.005), low frequency (0.05>MAF≥0.005), and common (MAF≥0.05). Visual 
examination of the distribution of the allele frequencies in the sample (Figure S1) highlights a 
natural grouping of these three frequency classes in this dataset. 
  In the primary analytic model, low frequency and rare variants were collapsed into an 
aggregate low frequency variant term and aggregate rare variant term, respectively. Specifically, 
individuals with at least one copy of the minor allele for any of the nonsynonymous and 
frameshift variants were coded as 1 in each variant class (rare or low frequency) and individuals 
without any minor allele copies in this class were coded as 0. This collapsing method was based 
on a burden test (Li and Leal, 2008) to increase power to detect the cumulative effect of these 
variant classes.  
Main effects of the one common rs16969968 coding variant, aggregate low frequency 
variants, and aggregate rare variants were analyzed together in a multivariate model of case-
control status (multivariate model set 1). This approach was used to examine the effect of low 
frequency and rare variants conditioned on the effect of the well-established common 
rs16969968 variant. The primary logistic regression model was logit(p)=β0+βG1rs16969968+ 
βG2LowFrequencyTerm+βG3RareTerm+βCC where C is the vector of standard covariates. 
  In secondary analyses, we examined the three low frequency variants (rs2229961, 
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rs80087508, rs79109919) as individual terms together with the common rs16969968 variant and 
aggregate rare variants (multivariate model set 2).  The secondary logistic regression model was 
logit(p)=β0+βG1rs16969968+βG2rs2229961+βG3rs80087508+βG4rs79109919+βG5 RareTerm+βCC. 
Because very few people were homozygous for the minor allele of the low frequency variants (0-
5 individuals per variant), the heterozygous and homozygous individuals for each minor allele 
were collapsed into a single group and compared to the homozygous individuals of the major 
allele in these secondary analyses.   
 
Explaining phenotypic variation 
To examine the variation in nicotine dependence explained by CHRNA5 coding variants, 
we used Nagelkerke’s adjusted R2 from logistic regression of case-control status (Nagelkerke, 
1991). The variance in phenotype attributed to selected variants was derived as the R2 
attributable to the full model minus the R2 attributable to the base model alone, including only 
age, sex, and first ancestry-specific PC as predictors of outcome. European and African 
American samples were analyzed separately. Each SNP or aggregate term was first examined 
individually. We then examined the final multivariate model sets 1 and 2. 
 
Replication samples 
The common and low frequency CHRNA5 variants were assessed in 12 independent 
replication datasets with smoking phenotypes and exome chip genotypes. Cigarettes smoked per 
day (CPD), a proxy for nicotine dependence, was used as the outcome because FTND scores 
were not available. Our replication analyses compared light smokers (CPD≤10) to heavy 
smokers (CPD>20) aged 25-80 years old. Previous work has demonstrated that these thresholds 
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of CPD agree with nicotine dependence defined by FTND (Berrettini et al, 2008; Stevens et al, 
2008). European and African Americans were examined in separate logistic regression models 
that were similar to the primary sample models without the rare variant term. Specifically, the 
primary replication model was logit(p)=β0+βG1rs16969968+βG2LowFrequencyTerm+βCC, and 
the secondary replication model was 
logit(p)=β0+βG1rs16969968+βG2rs2229961+βG3rs80087508+ βG3rs79109919+βCC, where C is 
the vector of standard covariates sex, age, ancestry-specific PCs, and field center (if applicable). 
For each ancestry group, all replication studies were required to have at least 50 light and 50 
heavy smokers to be included in analyses of that group. 
 
Meta-Analysis 
A series of meta-analyses involving the 12 replication datasets were performed using 
PLINK (Purcell et al, 2007). First, beta values for the genetic factors obtained from 
multivariable model sets 1 and 2 stratified by ancestry were meta-analyzed using weighting by 
standard errors. Each of these meta-analyses were then repeated with the addition of the beta 
from the primary dataset. Although examination of the Q statistic suggested no heterogeneity 
across studies for any of the genetic factors in any of the meta-analyses (p>0.1), except 
rs16969968 in European Americans (p=0.02)(Multivariable model sets 1 and 2 with and without 
primary sample), to be consistent and conservative, all reported meta-analysis results are from 
random effects models.  Some of the individual low frequency variants in multivariable model 
set 2 were found in a limited number of individuals in certain studies. An ancestry specific 
sample was excluded from the meta-analysis of one of the low-frequency variants, if the minor 
allele of that variant occurred less than 5 times in the sample. 
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5.4 RESULTS 
 
Variants identified in Sequencing 
Sequencing initially identified 30 coding variants in CHRNA5, including 4 frameshift 
deletions and 26 non-synonymous variants. Four variants failed the stringent quality control 
metrics. Specifically, three variants were removed based on the review performed by the Quality 
Assurance/Quality Control analysis team: p.Ala10fs had low sequencing depth, p.434_435del 
was located at the wrong position, and p.Ile80Thr had a mean reference allele fraction 
significantly deviated from 0.5. Finally, p.Ser6Leu was excluded because sequence information 
was missing for 8% of the sample.  
The remaining 26 CHRNA5 variants (24 nonsynonymous and 2 frameshift) included in 
this analysis were rated as high quality in the manual review and were available in the entire 
sample (details of these variants are listed in Supplemental Table 5.1 and Figure 5.1). The 
majority are projected to be deleterious through protein prediction programs (Gonzalez-Perez 
and Lopez-Bigas, 2011).  
 
Common CHRNA5 variant 
 The only common coding variant identified was the previously well-studied rs16969968 
located in the cytoplasmic domain of CHRNA5. In the primary sample, the rs1696968 minor 
allele was associated with increased risk for nicotine dependence in European (OR=1.3, 
p=0.003) and African Americans (OR=1.5, p=0.04) (Multivariate model set 1, Table 5.2). 
Replication results from 12 independent studies support the hypothesis that the A allele of 
rs16969968 increases risk for heaviness of smoking (Figure 5.2, Supplemental Tables 5.2-5.3). 
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Meta-analyses combining results from the primary and replication datasets demonstrate the 
robust role of rs16969968 (European: OR=1.3, p=3.7x10-11; African: OR=1.3, p=0.01). 
 
Aggregate low frequency CHRNA5 variants 
Three low frequency non-synonymous CHRNA5 variants were identified (Figure 1). To 
increase power to detect associations, our primary analyses used an aggregate low frequency 
variant term, comparing individuals with at least one minor allele of a low frequency variant to 
those without any (6 individuals in the primary sample had 2 copies of a low frequency variant 
and 1 individual had 2 different low frequency variants). In the primary Multivariate Model set 
1, this aggregate low frequency term provided trending evidence for association in both 
populations (European: OR=1.8, p=0.06; African: OR=1.4, p=0.07) (Table 5.2). Results from 
the replication studies demonstrated a significant combined effect of the three low frequency 
variants on heaviness of smoking (European: OR=1.2, p=0.02; African: OR=1.4, p=0.004) 
(Figure 5.1, Supplemental Tables 5.2-5.3). The overall meta-analysis from the primary and 
replication samples further illustrated the robust risk effect of the aggregate low frequency 
variants in both European (OR=1.3, p=0.005) and African Americans (OR=1.4, p=0.0006). 
 
Individual low frequency CHRNA5 variants 
 In secondary analyses using multivariate model set 2, we examined the independent 
contributions of the three low frequency variants to nicotine dependence risk controlling for the 
effect of other CHRNA5 coding variants. One of these low frequency variants was found 
primarily in European Americans, and the other two were found almost exclusively in African 
Americans (Table 5.2).   
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The first low frequency variant rs2229961 causes a valine to isoleucine change at 
position 134 in the extracellular domain. The minor allele principally occurred in European 
Americans (MAF=0.02) and was rare in African Americans (MAF=0.002) (Table 5.2). In the 
primary sample, all 51 individuals with a copy of rs2229961 also possessed at least one copy of 
the well-established rs16969968 minor allele, suggesting that these two coding variants are 
transmitted together. Controlling for the effect of rs16969968, the minor allele of rs2229961 was 
in the risk direction in European (OR=1.7, p=0.1) and African Americans (OR=2.6, p=0.4). 
Meta-analysis of these primary results and the independent replication samples provided strong 
evidence that this variant contributed a risk effect in European Americans (OR=1.3, p=0.007) 
where it predominantly occurs (Supplemental Table 5.4). 
The minor allele of the second low frequency variant rs80087508 causes a lysine to 
arginine transition at position 167 in the extracellular domain. This variant occurred exclusively 
in African Americans in both the primary sequencing sample (MAF=0.01, Table 5.2) and in the 
replication studies (Supplemental Table 5.5). This variant co-occurred with the common 
rs16969968 minor allele in 5 out of 38 individuals in the primary sample. In multivariable model 
set 2 controlling for other coding variants, the minor allele of rs80087508 trended in the risk 
direction in African Americans (OR=2.1, p=0.06) (Table 2). Meta-analysis of these primary 
results and the 12 independent replication samples provided evidence that this variant 
contributed an independent risk effect in African Americans (OR=1.6, p=0.02) where it 
exclusively occurred (Supplemental Table 5.5). 
The final low frequency variant, rs79109919, causes a leucine to glutamine change at 
amino acid position 363, which is located in the cytoplasmic domain (Figure 5.1). The minor 
allele of rs79109919 was common in African Americans (MAF=0.06) and occurred in only one 
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European American individual (MAF=0.0003) in the primary sample. Of the 158 individuals 
who possessed at least one copy of the rs79109919 minor allele, 7 also possessed a copy of the 
common rs16969968 risk allele and 1 possessed a copy of the low frequency rs80087508 variant, 
suggesting the independent transmission of these variants. In the primary sample, the minor 
allele of rs79109919 was in the risk direction in African Americans (OR=1.3, p=0.15) (Table 
5.2). Meta-analysis of the primary and replication results provided strong evidence that this 
variant contributed an independent risk effect in African Americans (OR=1.4, p=0.03) where it 
primarily occurred (Supplemental Table 5.5). 
  
Aggregate rare CHRNA5 variants 
Sequencing identified 22 rare coding variants (MAF<0.5%), including 20 
nonsynonymous variants and 2 frameshift deletions. These variants occurred throughout the 
protein sequence (Figure 5.1). Each variant occurred in 1-4 individuals in the primary sample 
(Supplemental Figure 5.1). Furthermore, 9 of the 22 rare variants were seen in a single 
individual and were previously unreported in large reference datasets (Abecasis et al, 2012) 
(Exome Variant Server) (Supplemental Table 5.1).  
Because these variants occurred in only a limited number of individuals, we used a 
collapsing burden test to assess their cumulative effect. Overall, 37 individuals possessed at least 
1 rare variant, including 34 individuals with only one rare variant and 3 individuals (2 cases and 
1 control) with 2 rare variants. In the primary sample, the aggregate rare variant term was 
associated with a risk effect in the European Americans (OR=12.9, p=0.01) as 12/13 (92%) 
individuals with at least one rare variant were cases (Table 5.2). In African Americans, the rare 
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variant term was in the risk direction but not significant (OR=1.5, p=0.37) as 17/24 (71%) of the 
individuals with at least one rare variant were cases. 
 
Phenotypic variation accounted for by testing genetic factors 
 Nagelkerke’s adjusted R2 was used to assess the proportion of nicotine dependence 
variation explained by individual SNPs and multivariable models in the primary sample (Table 
5.3). The well-studied rs16969968 gave the single strongest R2 of 1.0% in European Americans 
and a lower R2 of 0.4% in African Americans, where the variant is less common. In African 
Americans, the two low frequency variants, rs80087508 and rs79109919, which each occurred 
independently of rs16969968, gave R2 estimates of 0.3% and 0.1%, respectively. In European 
Americans, the low frequency variant rs2229961 gave an R2 of 0.4%.  Finally, the aggregate rare 
variant term had a high R2 of 1.0% in European Americans and a lower R2 of 0.1% in African 
Americans. 
 In multivariate models with common, low frequency, and rare CHRNA5 coding variants, 
the overall phenotypic variance explained by the genetic variants was 2.4% in European 
Americans and 1.0% in African Americans (multivariate model set 2, Table 5.3), supporting our 
conclusion that substantial variation in liability to nicotine dependence is attributable to 
CHRNA5 coding variation.  
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5.5 DISCUSSION 
 
Mounting evidence demonstrates that the functional rs16969968 variant in CHRNA5 
strongly contributes to differences in the risk of developing nicotine dependence across diverse 
populations (Chen et al, 2012b; Saccone et al, 2009). Here we show that multiple independent 
CHRNA5 coding variants increase risk of nicotine dependence in European and African 
Americans by examining targeted next-generation sequencing data of approximately 3 000 
nicotine dependent cases and non-dependent controls, with replication of low frequency variants 
using exome chip data in over 20 000 smokers.  
Targeted sequencing of CHRNA5 provided evidence that common, low frequency, and 
rare coding variants are independently associated with an increased risk of nicotine dependence, 
extending previous sequencing studies of other smoking-related measures. Wessel et al (2010) 
sequenced exons of CHRNA5 and other nicotinic receptors in 448 European American 
participants enrolled in a smoking cessation trial. Using a weighted allele sharing test, this study 
provided initial evidence that both common and rare variants contribute to level of FTND score 
(pseudo-F=3.92, p=0.046). Haller et al (2012) used pooled sequencing to examine 5 nicotinic 
receptor subunit genes (including CHRNA5) in 400 European and 352 African Americans from a 
sample, which also contributed 511 participants to our study. Pooled sequencing identified 5 
CHRNA5 coding variants. The well-studied rs16969968 was the only variant that exhibited a 
significant effect on nicotine dependence (p<0.05), yet the minor allele of all but one of the 
coding variants trended in the risk direction. Doyle et al (2014) sequenced 250 African American 
heavy smokers and identified a few coding variants, including a novel frameshift deletion, which 
the authors hypothesized leads to nonsense mediated decay. Our results build on these findings 
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by sequencing a large, diverse, unrelated sample (n=2 820), which enabled us to identify many 
coding variants of high quality (n=26), including 9 novel variants. 
Using exome chip data from 12 studies containing over 10 000 heavy and 10 000 light 
smokers, we confirmed that common and low frequency CHRNA5 coding variants identified 
through targeted sequencing had a robust association with smoking behaviors. Previously, Vrieze 
et al (2014) used the HumanExome BeadChip array to assess the effect of nonsynonymous 
variants on addiction and behavioral disinhibition in a European ancestry sample.  Examining 3 
412 individuals from 1 694 families exposed to nicotine, this study identified 8 nonsynonymous 
CHRNA5 variants. In single variant tests, rs16969968 (MAF=0.34) and rs2229961 (MAF=0.01) 
had a trending risk effect with a bonferroni corrected threshold (p=0.015 and p=0.046, 
respectively) on a composite nicotine dependence phenotype derived from factor analysis of 
frequency (days per month), quantity (cigarettes per day), and symptoms of dependence. The 6 
other nonsynonymous variants were rare (each occurred in 1-5 individuals), and the majority 
were in the risk direction in single variant tests. When considered together using burden tests, 
these rare variants did not reach the adjusted significance threshold (SKAT p-value=0.049). Our 
replication study design of examining phenotypic extremes of smoking quantity (heavy vs light 
smokers) using a large diverse sample facilitated the detection of strong associations between 
common and low frequency nonsynonymous CHRNA5 variants and heaviness of smoking. 
An important strength of our study was the large sample of African Americans (n=1 388), 
a population often under-represented in genetic studies.  Differences in the genetic architecture 
of European and African ancestry groups indicate that distinct genetic factors contribute to 
nicotine dependence in these populations. These differences are highlighted by the fact that the 
well-established rs16969968 variant is substantially more common in European (MAF=0.35) 
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than African Americans (MAF=0.06). We provide new evidence that two low frequency variants 
primarily occurring in African Americans (rs80087508 and rs79109919) independently 
contribute to nicotine dependence risk. 
Since multiple independent CHRNA5 signals were identified, a critical question is what 
proportion of phenotypic variance is explained by coding variation in this gene. Previous genetic 
studies of complex traits have identified reproducible associations, but these findings often 
explain only a modest proportion of phenotypic variance (Maher, 2008). For nicotine 
dependence, rs16969968 is arguably the single strongest genetic risk factor in European ancestry 
populations, and our results demonstrate that this variant only accounts for 1.0% of variance in 
European Americans (Table 3). However, the addition of low frequency and rare coding variants 
increased the estimated explained phenotypic variance in European Americans (R2=2.4%). In 
African Americans, rs16969968 is less common and therefore explains a smaller proportion of 
estimated phenotypic variance (R2=0.4%), and adding low frequency and rare coding variants 
increased this estimate (R2=1.0%). These results highlight that low frequency and rare coding 
variants, beyond the genome-wide significant common variant, increased the estimated variance 
in nicotine dependence attributable to CHRNA5. An important next step is to examine variation 
explained by these coding variants on biomarkers, which more closely resemble tobacco 
exposure (Bloom et al, 2014; Munafo et al, 2012). Bloom et al (2014) found that rs16969968 
explained four times more of the variance in carbon monoxide levels compared to self-reported 
cigarette consumption. Low frequency and rare CHRNA5 coding variants will likely add to the 
phenotypic variance of biomarkers and long-term disease.  
The findings reported here have limitations. This analysis focused on coding variants in 
CHRNA5 because the common nonsynonymous rs16969968 variant is associated with changes 
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in receptor function (Bierut et al, 2008; Kuryatov et al, 2011) and we hypothesized that other 
coding variants may have a similar effect.  Several noncoding variants tagged by rs588765 have 
been previously associated with changes in CHRNA5 mRNA expression levels in the brain 
(Wang et al, 2009a; Wang et al, 2009b; Wang et al, 2013). Our analysis does not address the 
contribution of noncoding CHRNA5 variation to nicotine dependence, which could influence our 
observed findings. Another limitation is that our analysis is restricted to a single gene. Previous 
studies (Saccone et al, 2010; Wessel et al, 2010) suggest that variation in other nicotinic 
receptors contribute to nicotine dependence. Specifically, recent evidence supports that rare 
variants in CHRNA3 and CHRNA4 are protective for nicotine dependence (Haller et al, 2012; 
Slimak et al, 2014; Xie et al, 2011). However, CHRNA5 is clearly associated with nicotine 
dependence, making it a high priority first gene for study.  
In summary, this study provides evidence that common, low frequency, and rare coding 
variants in CHRNA5 independently increase risk for nicotine dependence in both European and 
African Americans as well as explain a substantial proportion of variance of this disease. 
Importantly, we identify associations with nicotine dependence for three low frequency non-
synonymous variants, two of which almost exclusively occur in African Americans. From a 
public health perspective, these newly identified CHRNA5 variants may have important 
prognostic and therapeutic implications on an individual level. Beyond nicotine dependence, 
previous studies show that rs16969968 is the strong genetic risk factor for lung cancer and 
chronic obstructive pulmonary disease (Amos et al, 2008; Hung et al, 2008; Pillai et al, 2009; 
Thorgeirsson et al, 2008) as well as influences response to smoking cessation therapies (Chen et 
al, 2012a). An important next step is to test whether these low frequency and rare CHRNA5 
coding variants similarly increase the risk of smoking-related diseases and response to smoking 
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cessation. Expanding our knowledge of which genetic variants influence risk for long-term 
diseases and response to treatments will inform personalized medical care for smokers. 
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5.8 TABLES 
 
Table 5.1. Characteristics of primary sample 
 
 
aFTND is the Fagerstrom test for Nicotine Dependence 
bCPD is categorical cigarettes per day (1 is ≤10, 2 is 11-20, 3 is 21-30, 4 is >30);  
  
European American 
(n=1 432) 
African American 
(n=1 388) 
  cases controls cases controls 
Sample, n 728 704 854 534 
Age, mean (range) 37 (25-45) 36 (25-45) 36 (25-45) 36 (25-45) 
Sex     
   Female 386 (53%) 482 (68%) 514 (60%) 321 (60%) 
   Male 342 (47%) 222 (32%) 340 (40%) 213 (40%) 
FTNDa score, mean (range) 6.49 (4-10) 0.02 (0-1) 6.21 (4-10) 0.33 (0-1) 
CPDb category, mean (range) 1.94 (0-3) 0.01 (0-1) 1.11  (0-3) 0.03 (0-1) 
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Table 5.2. The effect of common, low frequency, and rare CHRNA5 coding variants on nicotine 
dependence in primary sample 
 
 
Multivariable model set 1 includes rs16969968, the aggregate low frequency variant term, and 
the aggregate rare variant term: 
Multivariable model set 2 includes rs16969968, rs2229961, rs800087508, rs79109919, and the 
aggregate rare variant term; 
All models adjusted for sex, age, and first ancestry-specific PC as covariates;  
*MAF stands for minor allele frequency; **for aggregate terms, the MAF was estimated by the 
dividing the number of people with at least one low frequency/rare variant by 2 times the total 
number of people; *** rs80087508 is non-polymorphic in European Americans; **** Because 
the minor allele of rs79109919 occurred less than 5 times in European Americans, the OR and p-
value are not presented.  
Variant Class Variant 
European Americans (n=1 432) African Americans (n=1 388) 
MAF* OR (95% CI) p-value MAF OR (95% CI) 
p-
value 
Multivariable Model set 1 
Common rs16969968 0.355 1.27  (1.08-1.49) 0.003 0.058 
1.46  
(1.02-2.07) 0.04 
Low Frequency Aggregate term** 0.016 
1.81  
(0.97-3.42) 0.06 0.071 
1.35  
(0.98-1.87) 0.07 
Rare Aggregate term 0.005 
12.90 
 (1.66-100.54) 0.01 0.009 
1.47  
(0.60-3.59) 0.40 
Multivariable Model set 2 
Common rs16969968 0.355 1.28  (1.09-1.50) 0.003 0.058 
1.42  
(1.00-2.03) 0.05 
Low Frequency 
rs2229961 0.016 1.71  (0.91-3.23) 0.10 0.002 
2.57 
 (0.28-23.91) 0.40 
rs80087508 0*** . . 0.014 2.00  (0.94-4.27) 0.07 
rs79109919 0.0003 **** . . 0.057 
1.22 
 (0.86-1.75) 0.26 
Rare Aggregate term 0.005 
12.91  
(1.66-100.66) 0.01 0.009 
1.51  
(0.62-3.68) 0.37 
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Table 5.3. Variation in nicotine dependence risk explained by selected variants and multivariate 
models in primary sample 
 
 
 
R2 is the Nagelkerke’s adjusted R2 difference from logistic regression, comparing the base model 
with intercept, sex, age, and ancestry specific PCs to models with genetic variants;  
Each individual variant and aggregate term was examined first by itself and then we examined 
the final multivariate model sets 1 and 2; 
Multivariable model set 1 includes rs16969968, the aggregate low frequency variant term, and 
the aggregate rare variant term: 
Multivariable model set 2 includes rs16969968, rs2229961, rs800087508, rs79109919, and the 
aggregate rare variant term; 
p-values calculated by taking the difference between the -2logliklihoods in the base model and 
those with variants as a chi-square statistic.  
Variant Class Variant 
European Americans (n=1 432) African Americans (n=1 388) 
MAF R2 p-value MAF R2 p-value 
Common rs16969968 0.355 1.0% 0.001 0.058 0.4% 0.04 
Low Frequency 
aggregate term 0.016 0.5% 0.02 0.071 0.3% 0.06 
rs2229961 0.016 0.4% 0.03 0.002 0.1% 0.24 
rs80087508 0 . . 0.014 0.3% 0.07 
rs79109919 0.0003 0.2% 0.15 0.057 0.1% 0.34 
Rare aggregate term 0.005 1.0% 0.0009 0.009 0.1% 0.37 
Multivariable model set 1  2.3% 1.2x10-5  0.8% 0.04 
Multivariable model set 2  2.4% 5.5 x10-5  1.0% 0.07 
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5.9 FIGURES 
 
Figure 5.1. Protein Schematic of CHRNA5 nonsynonymous and frameshift variants. Bold 
underline indicates the only common variant (MAF>5%); Bold indicates low frequency variants 
(5%>MAF≥0.5%); Other variants are rare (MAF<0.5%). 
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Figure 5.2. Forest plots showing the primary sample, replication samples, and random effects 
meta-analyses from Multivariable model set 1. (a) rs1696998 in European Americans; (b) 
aggregate low frequency variant term in European Americans; (c) rs1696998 in African 
Americans; (d) aggregate low frequency variant term in African Americans. 
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5.10 SUPPLEMENTAL METHODS 
 
Targeted sequencing of CHRNA5 
Custom baits were designed using Agilent’s web-based design tool eArray 
(https://earray.chem.agilent.com/earray) to capture regions with 50 kilobases on either side of the 
gene.  For library preparation, samples were placed on 96-well plates that were stratified by 
case/control status, recruitment study site, ethnicity, and sex.  A range of 500ng to 1ug of 
genomic DNA was sheared using the Covaris E-210 instrument using modified parameters for 
shearing (DutyCycle=10%, Intensity=4, Cycles per Burst=200, time=80sec).  Libraries were 
prepared according to the Agilent protocol (SureSelectXT Target enrichment for Illumina 
Multiplexed Sequencing Protocol v1.1.1). Amplification of the libraries prior to and post capture 
were performed using the Kapa Biosystems HiFi HotStart Ready Mix.  Samples were clustered 
for sequencing using the Illumina cBOT Cluster Generation system.  One hundred base pairs 
paired end sequencing was performed on the Illumina HiSeq 2000 platform v3 chemistry.  FastQ 
files were aligned with BWA (Li and Durbin, 2010) to the 1000 genomes phase 2 (GRCh37) 
human genome reference (Abecasis et al, 2012).  GATK2.3-9 was used for base quality 
recalibration and local realignment.  Unified Genotyper was used for multi-sample calling and 
VQSR for variant filtering.  All samples had 96-SNP barcode genotyping for sample identity 
tracking and concordance checking.   
 
Quality Control Measures 
Data quality was systematically evaluated using a robust alignment and variant calling 
workflow implemented by CIDR (http://www.cidr.jhmi.edu/index.html). Over 100 quality 
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control metrics were evaluated in real time to quickly identify potential errors and implement 
fixes throughout the sequencing process. Briefly, samples underwent pretesting with 96 SNP 
barcode panels, and more than 50% of samples also had previously acquired GWAS array data to 
verify sample identity and quality. Sample sex was confirmed by examining normalized read 
depth on the X and Y chromosomes. 64 duplicate samples and 65 HapMap controls were also 
used to assess the quality of variant calls. 
 
References: 
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al (2012). An 
integrated map of genetic variation from 1,092 human genomes. Nature 491(7422): 56-
65. 
Li H, Durbin R (2010). Fast and accurate long-read alignment with Burrows-Wheeler transform. 
Bioinformatics (Oxford, England) 26(5): 589-595 
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5.11 SUPPLEMENTAL REPLICATION STUDY DESCRIPTIONS 
 
Atherosclerosis Risk Communities Study (ARIC) 
The ARIC study has been described in detail previously.1 Men and women aged 45-64 years at 
baseline were recruited from four communities: Forsyth County, North Carolina; Jackson, 
Mississippi; Minneapolis, Minnesota; and Washington County, Maryland. A total of 15,792 
individuals, predominantly White and African American, participated in the baseline 
examination in 1987-1989, with three additional triennial follow-up examinations and a fifth 
exam in 2011. Informed consent was obtained from all participants, and this project was 
approved by the Institutional Review Boards of all participating institutions. The current analysis 
included 3 366 European Americans (1 859 Heavy smokers and 1 507 Light smokers) and 922 
African Americans (214 heavy smokers and 708 light smokers) with available Illumina Infinium 
Human Exome Array v1.0 data.2 
 
Reference: 
1. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and 
objectives. Am J Epidemiol 129, 687-702 (1989). 
2. Grove, M.L., Yu, B., Cochran, B.J., Haritunians, T., Bis, J.C., Taylor, K.D., Hansen, M., 
Borecki, I.B., Cupples, L.A., Fornage, M., et al. (2013). Best practices and joint calling of the 
HumanExome BeadChip: the CHARGE Consortium. PLoS ONE 8, e68095. 
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Cardiovascular Health Study (CHS) 
This is a population-based cohort study of risk factors for the development and progression of 
cardiovascular disease in older adults sponsored by the by the NHLBI.1 Between 1989 and 1990, 
this study recruited 5201 adults ages 65 and older from four U.S. communities, and recruited an 
additional predominately African-American cohort of 687 people in 1992-1993. Subjects 
received annual clinic follow-up and semi-annual phone calls. Informed consent was obtained 
from all participants, and this project was approved by the Institutional Review Boards of all 
participating institutions. The current analysis included 1 370 European Americans (513 Heavy 
smokers and 857 Light smokers) and 312 African Americans (50 heavy smokers and 262 light 
smokers) with available Illumina HumanExome BeadChip v1.0 data. 
 
Reference: 
1. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio 
TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann 
Epidemiol. 1991; 1(3):263-76 
 
Collaborative Study on the Genetics of Alcoholism (COGA) 
COGA was initiated in 1989 as a large, family study designed to identify genes that contribute to 
alcohol use disorders and related behaviors funded by the National Institute on Alcohol Abuse 
and Alcoholism.1,2 Alcoholic probands were recruited from treatment facilities from seven sites 
across the US. Family members of these probands were invited to participate and a set of 
comparison families was also drawn from the same communities. COGA has gathered detailed, 
standardized data on study participants, including diagnostic, genetic, and neurophysiological 
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assessments. COGA continues to enroll young participants from these families in a longitudinal 
study to examine the development of substance use disorders. Informed consent was obtained 
from all participants, and this project was approved by the Institutional Review Boards of all 
participating institutions. The current analysis included 340 European Americans (208 Heavy 
smokers and 132 Light smokers) with available Affymetrix Axiom Exome 319 array data. 
 
References: 
1. Begleiter H, Reich T, Hesselbrock V, Porjesz B, Li T, Schuckit M, Edenberg H, Rice J (1995) 
The Collaborative Study on the Genetics of Alcoholism. Alcohol Health Res World 19:228–236 
2. Edenberg, H. J. (2002) The Collaborative Study on the Genetics of Alcoholism: 
an update. Alcohol Res Health 26, 214-218., 
 
Erasmus Rucphen Family study (ERF) 
This is a family-base cohort study, which is part of the Genetic Research in isolated Populations 
(GRIP) program.1,2 The goal of this study is to identify genetic risk factors in the development of 
complex disorders within a genetically isolated population in the southwest of the Netherlands. 
In this study, 22 couples that had at least 6 children baptized in the community church from 
1850-1900 were identified. All living descendants and their spouses were invited to participate. 
Study population includes ~3000 individuals. All data were collected between 2002 and 2005. 
Subjects received extensive clinical evaluations at a research center within the community. 
Informed consent was obtained from all participants, and this project was approved by the 
Institutional Review Boards of all participating institutions. The current analysis focused on 215 
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Europeans (77 Heavy smokers and 138 Light smokers) with available Illumina HumanExome 
chip v1.1 data. 
 
References: 
1. Aulchenko YS, Heutink P, Mackay I, Bertoli-Avella AM, Pullen J, Vaessen N,  Rademaker 
TA, Sandkuijl LA, Cardon L, Oostra B, van Duijn CM. Linkage disequilibrium in young 
genetically isolated Dutch population. Eur J Hum Genet 2004;12:527–34 
2. Henneman P, Aulchenko YS,  Frants RR, van Dijk KW, Oostra BA, van Duijn CM. 
Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch 
isolate: the Erasmus Rucphen Family study J Med Genet 2008;45:572-577 
 
Family Heart Study (FamHS) 
The FamHS (https://dsgweb.wustl.edu/fhscc/ ) is a multi-center, population-based study of 
genetic and nongenetic determinants of coronary heart disease (CHD), atherosclerosis, and 
cardiovascular risk factors. This study began in 1992 with the ascertainment of 1,200 families, 
half randomly sampled and half selected because of an excess of CHD or risk factor 
abnormalities as compared with age- and sex-specific population rates.1 The families, with 
approximately 6,000 subjects, were sampled from four population-based parent studies. The 
participants attended a first clinic visit between the years 1994-1996 and a broad range of 
phenotypes was assessed in the general domains of CHD, atherosclerosis, cardiac and vascular 
function, inflammation and hemostasis, lipids and lipoproteins, blood pressure, diabetes and 
insulin resistance, pulmonary function, diet, habitual physical activity, anthropometry, medical 
history and medication use. Approximately 8 years later, 2,756 European American (EA) 
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subjects belonging to the 510 of the largest and most informative pedigrees were invited for a 
second clinical visit (2002-04). The most important CHD risk factors were measured again. 
Medical history and medication use was updated. Informed consent was obtained from all 
participants, and this project was approved by the Institutional Review Boards of all participating 
institutions. FamHS participants were genotyped on the HumanExome Bead-Chip v.1.0 
(Illumina) and jointly called at the University of Texas Health Science Center at Houston. 
Informed consent was obtained from all participants, and this project was approved by the 
Institutional Review Boards of all participating institutions. The current analysis included 991 
European Americans (550 Heavy smokers and 441 Light smokers) from the first clinical visit in 
which has a total of 3,868 subjects with exome data.   
 
Reference: 
1. Higgins M, Province M, Heiss G, Eckfeldt J, Ellison RC, Folsom AR, Rao DC, Sprafka JM, 
Williams R. NHLBI Family Heart Study: objectives and design.  Am J Epidemiol. 1996 Jun 15; 
143(12):1219-28. 
 
Genetic Epidemiology Network of Arteriopathy (GENOA) 
This is one of four research networks that form the NHLBI Family Blood Pressure Program.1,2 
The overall goal of GENOA is to elucidate the genetics of hypertension and its arteriosclerotic 
target-organ damage, including macrovascular and microvascular complications in heart, brain, 
kidneys, and peripheral arteries. From 1995 to 2000, two cohorts were ascertained through 
sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of 
age. All siblings were invited to participate.  Approximately 80% of participants received a 
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follow-up exam between 2000 and 2005. Informed consent was obtained from all participants, 
and this project was approved by the Institutional Review Boards of all participating institutions. 
The current analysis included 539 European Americans (258 Heavy smokers and 281 Light 
smokers) and 371 African Americans (73 Heavy smokers and 298 Light smokers) with available 
Illumina Infinium HumanExome BeadChip v1.1 data. 
 
References: 
1.FBPP Investigators. Multi-center genetic study of hypertension: The Family Blood Pressure 
Program (FBPP). Hypertension. 2002 Jan; 39(1):3-9. 
2. Daniels PR, Kardia SL, Hanis CL, Brown CA, Hutchinson R, Boerwinkle E, Turner ST, 
Genetic Epidemiology Network of Arteriopathy study.  Familial aggregation of hypertension 
treatment and control in the Genetic Epidemiology Network of Arteriopathy (GENOA) study.  
Am J Med. 2004 May 15; 116(10):676-81. 
 
Hypertension Genetics Epidemiology Network (HyperGEN) 
This is one of four research networks that form the NHLBI Family Blood Pressure Program.1,2 
The goal of HyperGEN is to identify major genetic determinants of hypertension and to study 
possible interactions between genetic and non-genetic factors in defined populations. African 
American and non-Hispanic white hypertensive siblings along with available parents and 
untreated adult offspring were recruited from 5 field centers across the US. Preference in 
ascertainment and recruitment was given to sibships with a least one subject with severe 
hypertension. Informed consent was obtained from all participants, and this project was approved 
by the Institutional Review Boards of all participating institutions. The current analysis included 
163 
 
715 African Americans (97 Heavy smokers and 618 Light smokers) with available Affymetrix 
Genome-Wide Human SNP Array 6.0 and 5.0 data. 
 
References: 
1. FBPP Investigators. Multi-center genetic study of hypertension: The Family Blood Pressure 
Program (FBPP). Hypertension. 2002 Jan; 39(1):3-9. 
2. Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, Eckfeldt JH, Leppert 
MF, Province MA, Mockrin SC, Hunt SC. NHLBI family blood pressure program: methodology 
and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann 
Epidemiol. 2000 Aug;10(6):389-400. 
 
Jackson Heart Study (JHS) 
This is a large, community-based, observational study to understand factors that influence heart 
disease and other illnesses in African Americans funded by the NHLBI and the Office of 
Research on Minority Health at NIH.1 JHS is an expansion of the ARIC study site in Jackson, 
Mississippi.  Since its inception in 1998, 5 301 African American men and women have been 
enrolled in this study from urban and rural areas in the Jackson, Mississippi metropolitan area. 
The study focused on individuals ages 35-84, except in the family cohort where individuals 21 to 
34 were also eligible. Three back-to-back cohort clinical exams were performed (2000-2004, 
2005-2009, and 2009-2012), providing extensive longitudinal data. Informed consent was 
obtained from all participants, and this project was approved by the Institutional Review Boards 
of all participating institutions. The current analysis included 495 African Americans (102 Heavy 
smokers and 393 Light smokers) with available Illumina HumanExome Chip v1.0 data. 
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Reference: 
1. Taylor HA Jr, Wilson JG, Jones DW, Sarpong DF, Srinivasan A, Garrison RJ, Nelson C, 
Wyatt SB. Toward resolution of cardiovascular health disparities in African Americans: design 
and methods of the Jackson Heart Study. Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-4-17. 
 
Multi-Ethnic Study of Atherosclerosis (MESA) 
This population-based cohort study was initiated in July 2000 to investigate the prevalence, 
correlates, and progression of subclinical cardiovascular disease.1 A total of 6 814 asymptomatic 
individuals’ ages 45-84 years olds were recruited from 6 field centers across the US. Each 
participant received an extensive clinical exam and blood samples were collected to test 
biochemical and genetic risk factors. Informed consent was obtained from all participants, and 
this project was approved by the Institutional Review Boards of all participating institutions. The 
current analysis included 819 European Americans (369 Heavy smokers and 450 Light smokers) 
and 546 African Americans (101 Heavy smokers and 445 Light smokers) with available Illumina 
HumanExome Chip v1.0 
data. 
 
Reference: 
1. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, 
Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP.  
Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002 Nov 1; 
156(9):871-81. 
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Rotterdam Study Cohort 1 (RS1) 
The Rotterdam Study is a prospective, population-based cohort study to determine the 
occurrence of cardiovascular, neurological, ophthalmic, endocrine, hepatic, respiratory, and 
psychiatric diseases in elderly people.1 Subjects were recruited from Ommoord, a suburb of 
Rotterdam, in three different cohorts. The initial cohort (RS1) began in 1990 with 7 983 
individuals aged 55 and older with follow-up visits in 1994-1995, 1997-1999, 2002-2004, and 
2009-2011. All participants were interviewed at home and received an extensive set of clinical 
examinations, including imaging and sample collection for molecular and genetic analyses. 
Informed consent was obtained from all participants, and this project was approved by the 
Institutional Review Boards of all participating institutions. The current analysis included 1 235 
Europeans (535 Heavy smokers and 700 Light smokers) with available Illumina HumanExome 
beadchip v1.0 data. 
 
Reference: 
1. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver 
CC, Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW. The 
Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013 Nov;28(11):889-
926. doi: 10.1007/s10654-013-9866-z. Epub 2013 Nov 21. PubMed PMID: 24258680. 
 
Women’s Genomic Health Study (WGHS) 
The Women’s Genome Health Study (WGHS) is a prospective cohort of initially healthy, female 
North American health care professionals at least 45 years old at baseline representing 
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participants in the Women’s Health Study (WHS) who provided a blood sample at baseline and 
consent for blood-based analyses. 1 The WHS was a 2x2 trial beginning in 1992-1994 of vitamin 
E and low dose aspirin in prevention of cancer and cardiovascular disease with about 10 years of 
follow-up.  Since the end of the trial, follow-up has continued in observational mode. Additional 
information related to health and lifestyle were collected by questionnaire throughout the WHS 
trial and continuing observational follow-up. Informed consent was obtained from all 
participants, and this project was approved by the Institutional Review Boards of all participating 
institutions. The current analysis included 6 540 European Americans (4 924 Heavy smokers and 
1 616 Light smokers) that had the common rs16969968 variant genotyped on the Illumina 
HumanHap300 Duo”+” and the three low frequency CHRNA5 variants genotyped on the 
Illumina exome v.1.1 chip. 
 
Reference: 
1. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE; Women's Genome 
Health Study Working Group. Rationale, design, and methodology of the Women's Genome 
Health Study: a genome-wide association study of more than 25,000 initially healthy american 
women. Clin Chem. 2008 Feb;54(2):249-55. Epub 2007 Dec 10. PubMed PMID: 18070814. 
 
Women’s Health Initiative (WHI) 
The WHI is a long-term national health study focused on strategies for preventing heart disease, 
breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. Between 
1993 and 1998, 161 808 postmenopausal women were enrolled from 40 clinical centers in either 
a clinical trial (68 132) or an observation study (93 676).1-4 The clinical trials were designed to 
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test the effects of postmenopausal hormone therapy, diet modification, as well as calcium and 
vitamin D supplements on disease outcomes. The observation study examined the relationship 
between lifestyle, environmental, medical, and other risk factors on specific measures of health.  
Recruitment was done through mass mailing to age-eligible women obtained from voter 
registration, driver’s license and Health Care Financing Administration or insurance lists, with 
target recruitment of a socio-demographically diverse population. WHI participants were also 
invited to participate in an extension study with follow-up through 2010. Informed consent was 
obtained from all participants, and this project was approved by the Institutional Review Boards 
of all participating institutions. The current analysis included 4 076 European Americans (2 065 
Heavy smokers and 2 011 Light smokers) and 610 African Americans (117 Heavy smokers and 
493 Light smokers) with available Illumina HumanExome BeadChip v1exome chip data. 
 
References: 
1. Design of the women's health initiative clinical trial and observational study. The women's 
health initiative study group. Control Clin Trials. 1998;19:61-109 
2. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein 
E, Prentice RL. Implementation of the women's health initiative study design. Ann Epidemiol. 
2003;13:S5-17 
3. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller 
LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, 
Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, 
Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf 
AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, 
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Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson 
KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: The women's health 
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4. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford 
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5.12 SUPPLEMENTAL TABLES 
Supplemental Table 5.1. Characteristics of 26 high quality CHRNA5 coding variants identified by targeted sequencing of 1 582 
Nicotine dependent cases and 1 238 controls. 
Position of 
variants 
dbSNP 
identifier 
Coding 
Change 
Protein 
Change 
Study MAFa, allele count frequency 
class in 
analysis 
Exome Sequencing Project 
MAF, allele count 
 Phase 1 1000 
Genomes 
MAF, allele 
count 
Condel 
Score 
(Class) 
Frameshift 
Deletions 
      European 
Ancestry 
(n=1,432) 
African 
Ancestry 
(n=1,388) 
  AA EA      
chr15:78882
385..788823
86   c.653delG p.Trp218fs   
0.0004, 
1(A1)/2775(R)  Rare 
0.000, 
1(A1)/4263(R)  
0.001, 
5(A1)/8247(R)      
chr15:78885
495..788855
00   
c.1308_131
2del p.436_438del  
0.0004, 
1(A1)/2775(R)  Rare         
Nonsynony
mous SNVs                     
chr15:78873
239   c.193G>C p.Val65Leu 
0.0003, 
1(C)/2863(G)   Rare       
0.712 
(deleterious) 
chr15:78873
288   c.242C>T p.Ser81Phe   
0.0004, 
1(T)/2775(C)  Rare       
0.861 
(deleterious) 
chr15:78879
017 rs148722844 c.289G>A p.Val97Ile   
0.0007, 
2(A)/2774(G) Rare 
0.000, 
1(A)/4391(G)     
0.386 
(neutral) 
chr15:78880
752 rs2229961 c.400G>A p. Val134Ile 
0.016, 
46(A)/2818(G) 
0.002, 
5(A)/2771(G) 
Low 
frequency 
0.003, 
14(A)/4378(G) 
0.019, 
165(A)/8421(G) 
0.006, 
13(A)/2171(G) 
0.905 
(deleterious) 
chr15:78882
176 rs201563436 c.443C>T p.Thr148Met   
0.0004, 
1(T)/2775(C)  Rare   
0.000, 
8585(C)/1(T)   
0.966 
(deleterious) 
chr15:78882
221 rs55863434 c.488C>T p.Pro163Leu 
0.0003, 
1(T)/2863(C)    Rare   
0.000, 
8583(C)/3(T)   
1.000 
(deleterious) 
chr15:78882
233 rs80087508 c.500A>G p. Lys167Arg   
0.014, 
39(G)/2737(A) 
Low 
frequency 
0.019, 
4308(A)/84(G) 
0.000, 
8585(A)/1(G) 
0.005, 
2174(A)/10(G) 
0.790 
(deleterious) 
chr15:78882
389   c.656A>C p.Glu219Ala 
0.0003, 
1(C)/2863(A)    Rare       
0.449 
(neutral) 
chr15:78882
446 rs61742337 c.713C>T p.Pro238Leu 
0.0007, 
2(T)/2862(C)    Rare   
0.000, 
8584(C)/2(T)   
0.883 
(deleterious) 
170 
 
chr15:78882
478 rs137878726 c.745C>A p.Leu249Met   
0.001, 
4(A)/2772(C)  Rare 
 0.000, 
2(A)/4390(C)      
0.841 
(deleterious) 
chr15:78882
529 rs138719535 c.796T>A p.Phe266Ile   
0.001, 
3(A)/2773(T)  Rare 
 0.001, 
3(A)/4389(T)     
0.858 
(deleterious) 
chr15:78882
682 rs116099178 c.949C>G p. Leu317Val   
0.001, 
4(G)/2772(C)  Rare 
 0.001, 
4389(C)/3(G)   
 0.001, 
2182(C)/2(G) 
0.411 
(neutral) 
chr15:78882
694 rs74865777 c.961A>G p.Met321Val 
0.0007, 
2(G)/2862(A)   Rare       
0.643 
(deleterious) 
chr15:78882
733   c.1000G>A p.Ala334Thr   
0.0004, 
1(A)/2775(G)  Rare       
0.473 
(deleterious) 
chr15:78882
809 rs79721430 c.1076C>T p. Thr359Met 
0.0003, 
1(T)/2863(C)    Rare   
 0.000, 
8584(C)/2(T) 
 0.000, 
2183(C)/1(T) 
0.027 
(neutral) 
chr15:78882
821 rs79109919 c.1088T>A p.Leu363Gln 
0.0003, 
1(A)/2863(T) 
0.058, 
160(A)/2616(T)  
Low 
frequency 
 0.052, 
228(A)/4164(T) 
 0.001,  
5(A)/8581(T) 
 0.021, 
46(A)/2138(T) 
0.871 
(deleterious) 
chr15:78882
925 rs16969968 c.1192G>A p.Asp398Asn 
0.355, 
1016(A)/1848(G)  
0.058, 
161(A)/2615(G)  Common 
 0.062, 
274(A)/4118(G) 
0.349, 
2993(A)/5593(G) 
0.175, 
383(A)/1801(G) 
0.018 
(neutral) 
chr15:78882
934 rs76766434 c.1202C>T p.Arg401Cys 
0.0003, 
1(T)/2863(C)  
0.0007, 
2(T)/2774(C)  Rare 
0.002, 
4385(C)/7(T) 
 0.000, 
8585(C)/1(T) 
 0.000, 
2183(C)/1(T) 
0.458 
(neutral) 
chr15:78882
935 rs141180754 c.1202G>A p.Arg401His   
0.001, 
3(A)/2773(G)  Rare 
 0.001, 
3(A)/4389(G)     
0.025 
(neutral) 
chr15:78882
953   c.1220C>T p.Ile407Thr  
0.0004, 
1(T)/2775(C)  Rare       
0.005 
(neutral) 
chr15:78885
462 rs202052590 c.1274A>G p.Gln425Arg 
0.0003, 
1(G)/2863(A)    Rare       
0.910 
(deleterious) 
chr15:78885
464 rs150329151 c.1276G>A p.Val426Ile   
0.0004, 
1(A)/2775(G)  Rare 
 0.000, 
1(A)/4391(G)     
0.746 
(deleterious) 
chr15:78885
574 rs76071148 c.1386T>A p.His462Gln 
0.0007, 
2(A)/2862(T)  
0.0007, 
2(A)/2774(T)  Rare 
 0.000, 
2(A)/4390(T) 
0.000, 
2(A)/8584(T) 
 0.076, 
166(A)/2018(T) 
0.340 
(neutral) 
chr15:78885
579   c.1391A>G p.Gly464Glu 
0.0003, 
1(G)/2863(A)    Rare       
0.88- 
(deleterious) 
 
aMAF is minor allele frequency. 
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Supplemental Table 5.2. Random effects meta-analysis results for multivariate model set 1 in European Americans 
 
 Heavy 
Smokers 
Light 
Smokers 
rs16969968 Aggregate low frequency 
variants 
 MAF* OR p-value MAF** OR p-value 
Primary sample*** 728 704 0.36 1.27 0.003 0.02 1.81 0.06 
Replication Studies         
   ARIC 1859 1507 0.33 1.44 1.03E-09 0.02 1.20 0.41 
   CHS 513 857 0.34 1.07 0.48 0.02 1.25 0.50 
   COGA 209 133 0.33 1.53 0.06 0.02 0.49 0.24 
   ERF 138 77 0.36 0.86 0.25 0.02 1.26 0.38 
   FamHS 550 441 0.34 1.45 0.0006 0.01 1.03 0.95 
   GENOA 258 281 0.37 1.39 0.01 0.01 0.97 0.96 
   MESA 369 450 0.33 1.30 0.02 0.01 1.35 0.48 
   RS1 535 700 0.30 1.16 0.11 0.01 1.73 0.17 
  WGHS 4924 1616 0.34 1.29 4.17E-09 0.02 1.45 0.01 
   WHI 2065 2011 0.36 1.33 3.05E-09 0.02 1.05 0.77 
   Meta-analysis 11420 8073  1.27 3.51E-09  1.23 0.02 
Overall****         
   Meta-analysis 12148 8777  1.27 3.69E-11  1.27 0.005 
 
Multivariable model set 1 includes rs16969968 and the aggregate low frequency variant term: 
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;  
*MAF stands for minor allele frequency; **For the aggregate low frequency variant terms, the MAF was calculated by the dividing 
the number of people with at least one low frequency/rare variant by the total number of people by 2; ***Primary sample compared 
nicotine dependent cases versus controls instead of heavy versus light smokers;  ****Overall meta-analysis included the primary and 
replication samples. 
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Supplemental Table 5.3. Random effects meta-analysis results for multivariate model set 1 in African Americans 
 Heavy 
Smokers 
Light 
Smokers 
rs16969968 Aggregate low frequency 
variants 
 MAF* OR p-value MAF** OR p-value 
Primary sample*** 854 534 0.06 1.46 0.04 0.06 1.46 0.04 
Replication Studies         
   ARIC 214 708 0.06 1.36 0.20 0.07 1.49 0.09 
   CHS 50 262 0.08 2.14 0.03 0.06 1.20 0.73 
   GENOA 73 298 0.05 1.93 0.09 0.08 1.38 0.35 
   HyperGEN 97 618 0.05 1.00 1.00 0.07 1.11 0.76 
   JHS 102 393 0.06 0.73 0.42 0.07 2.14 0.01 
   MESA 101 445 0.07 0.89 0.73 0.06 0.89 0.73 
   WHI 117 493 0.06 1.22 0.49 0.05 1.33 0.39 
   Meta-analysis 754 3217  1.24 0.10  1.42 0.004 
Overall****         
   Meta-analysis 1608 3751  1.30 0.01  1.40 0.0006 
 
Multivariable model set 1 includes rs16969968 and the aggregate low frequency variant term: 
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;  
*MAF stands for minor allele frequency; **For the aggregate low frequency variant terms, the MAF was calculated by the dividing 
the number of people with at least one low frequency/rare variant by the total number of people by 2;  ***Primary sample compared 
nicotine dependent cases versus controls instead of heavy versus light smokers;  ****Overall meta-analysis included the primary and 
replication samples. 
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Supplemental Table 5.4. Random effects meta-analysis results for multivariate model set 2 in European Americans 
 Heavy 
Smoker
s 
Light 
Smokers 
rs16969968 rs2229961 rs79109919 
 MAF* OR p-value MAF OR p-value MAF OR p-value 
Primary 
sample*** 728 704 0.36 1.28 0.003 0.02 1.71 0.10 0.0003** . . 
Replication 
Studies            
   ARIC 1859 1507 0.33 1.44 1.07E-09 0.02 1.20 0.41 0.0003** . . 
   CHS 513 856 0.34 1.07 0.49 0.02 1.27 0.47 0 . . 
   COGA 209 133 0.33 1.52 0.06 0.02 0.60 0.43 0.002** . . 
   ERF 138 77 0.36 0.86 0.25 0.02 1.26 0.38 0 . . 
   FamHS 548 438 0.34 1.46 0.0005 0.01 1.02 0.97 0 . . 
   GENOA 258 281 0.37 1.39 0.01 0.01 0.97 0.96 0 . . 
   MESA 369 450 0.33 1.29 0.02 0.01 1.45 0.40 0.0008** . . 
   RS1 535 700 0.30 1.16 0.11 0.01 1.73 0.17 0 . . 
  WGHS 4924 1616 0.34 1.29 6.15E-09 0.02 1.38 0.03 0.0004 3.50 0.21 
   WHI 2065 2011 0.36 1.34 2.14E-09 0.02 1.05 0.79 0.0006 2.01 0.45 
   Meta-analysis 11418 8069  1.27 3.72E-09  1.23 0.02  2.60 0.16 
Overall****            
   Meta-analysis 12146 8773  1.28 3.60E-11  1.26 0.007  2.60 0.16 
 
Multivariable model set 2 includes rs16969968, rs229961, rs8008750, and rs79109919. However, rs8008750 was non-polymorphic in 
European Americans in all of the studies so it is not included in this table. 
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;  
*MAF stands for minor allele frequency; ** Because the minor allele of rs79109919 occurred less than 5 times in the primary sample, 
ARIC, COGA, and MESA, these results were not included in the meta-analyses; ***Primary sample compared nicotine dependent 
cases versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and replication samples. 
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Supplemental Table 5.5. Random effects meta-analysis results for multivariate model set 2 in African Americans 
 
 Heavy 
Smokers 
Light 
Smokers 
rs16969968 rs2229961 rs8008750 rs79109919 
 MAF* OR p-value MAF OR p-value MAF OR p-value MAF OR p-value 
Primary 
sample*** 854 534 0.06 1.46 0.04 0.002 2.57 0.40 0.01 2.00 0.07 0.06 1.22 0.26 
Replication 
Studies               
   ARIC 214 708 0.06 1.49 0.11 0.005 0.51 0.46 0.02 1.04 0.94 0.05 1.70 0.03 
   CHS 50 262 0.08 2.11 0.04 0.005 1.60 0.73 0.01 1.74 0.54 0.04 0.93 0.92 
   GENOA 73 298 0.05 1.79 0.14 0.001** . . 0.01 1.35 0.74 0.07 1.10 0.81 
   HyperGEN 97 618 0.05 1.03 0.92 0.001** . . 0.02 1.13 0.84 0.05 1.12 0.78 
   JHS 102 393 0.06 0.89 0.78 0.004** . . 0.02 1.31 0.62 0.05 3.16 0.001 
   MESA 101 445 0.07 0.87 0.68 0.009 1.00 1.00 0.02 2.16 0.14 0.05 0.88 0.75 
   WHI 117 493 0.06 1.22 0.50 0.005 0.94 0.94 0.01 1.79 0.35 0.04 1.10 0.81 
   Meta-analysis 754 3217  1.29 0.04  0.85 0.77  1.43 0.12  1.39 0.06 
Overall****               
   Meta-analysis 1608 3751  1.33 0.005  1.06 0.91  1.56 0.02  1.36 0.03 
 
Multivariable model set 2 includes rs16969968, rs229961, rs8008750, and rs79109919.  
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates. 
*MAF stands for minor allele frequency; ** Because the minor allele of rs2229961 occurred less than 5 times in GENOA, 
HyperGEN, and JHS, these results were not included in the meta-analysis; ***Primary sample compared nicotine dependent cases 
versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and replication samples. 
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5.13 SUPPLEMENTAL FIGURE 
Supplemental Figure 5.1. Twenty-six CHRNA5 coding variants ordered based on minor allele 
frequency 
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CHAPTER SIX: 
Future steps to understand the role of targeted genes in substance use disorders  
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6.1 SUMMARY OF THE DISSERTATION 
 
Overall, this dissertation illustrates the discovery potential of analyses focused on 
dissecting associations between genome-wide significant genes and substance use disorders. 
First, I illustrate in chapter 2 that many previously identified candidate genes are not strongly 
associated with alcohol dependence in a large genome wide association (GWA) study, 
highlighting that GWA studies can clarify the role of candidate genes for substance use 
disorders. I then conducted several hypothesis-driven analyses focused on three functional 
candidate genes (ADH1B, CYP2A6, and CHRNA5) that have reached genome-wide levels for 
alcoholism or smoking in GWA studies.  By incorporating important environmental factors, 
critical developmental periods, and rare coding variants, I refined associations between these 
genes and substance use behaviors. In chapter 3, I showed that the high-risk environment of peer 
drinking eliminates the protective effect of an ADH1B variant on adolescent drinking milestones.  
In chapter 4, I demonstrated that a CYP2A6 metabolism metric was not associated with smoking 
initiation or daily smoking, but slow metabolism was associated with increased risk of nicotine 
dependence among daily smokers. Finally, in chapter 5, I provided evidence that low frequency 
and rare CHRNA5 coding variants contribute an independent risk effect to nicotine dependence.  
These findings add insight into the biological mechanisms that lead to alcohol and nicotine use 
disorders, two diseases with substantial public health implications in the US and worldwide 
(CDC, 2014, Stahre et al., 2014, WHO, 2014b, WHO, 2014a). 
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6.2 FUTURE DIRECTIONS 
 
Replication in independent samples 
 These studies provide new evidence for the role of targeted genes in the development of 
substance use disorders. Although some of these new findings were replicated in independent 
samples (e.g. role of metabolism metric on nicotine dependence in chapter 4 and effect of low 
frequency variants on smoking behaviors in chapter 5), an appropriate replication sample was not 
available to verify all of the association findings in this dissertation.  Replication of these 
findings in independent samples using a variety of different populations would provide 
additional evidence supporting the robustness and generalizability of our conclusions. 
 
Experiments to understand biological mechanisms  
 Association findings from the analyses presented in this dissertation have led to new 
hypotheses about the role of genetic variation in the development of substance use disorders.  An 
important next step is to experimentally test these hypotheses. For example, in chapter 6, I 
identified several low frequency and rare CHRNA5 coding variants that confer an independent 
risk for nicotine dependence beyond the common rs16969968 variant.  Previous biological 
studies of rs16969968 have shown that the risk A allele leads to decreased response to nicotine 
agonists in cell culture experiments (Bierut et al., 2008) as well as lower Ca2+ permeability and 
increased short term desensitization when incorporated into certain neuronal nicotinic receptors 
expressed in Xenopus laevis oocytes (Kuryatov et al., 2011).  Similar electrophysiology patch-
clamp experiments could be used to assess the functional effects of the newly identified low 
frequency and rare CHRNA5 coding variants.  Biological studies could inform our understanding 
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of the mechanisms by which these identified genetic variants alter risk for substance use 
disorders. 
 
Test additional hypotheses and build composite risk scores 
 By focusing on variation in ADH1B, CYP2A6, and CHRNA5, we have developed a 
framework for understanding how environmental factors, developmental periods, and rare 
variants influence the roles of targeted genes in substance use disorders.  This framework could 
also be used to test additional hypotheses that build on the findings presented in this dissertation. 
For example, beyond peer drinking, parental monitoring is a critical environment for the 
development of adolescent drinking behaviors and twin studies suggest that family factors 
modify heritable variation in youth alcohol involvement (Kendler et al., 2011, Miles et al., 2005). 
Based on our observation that the high-risk environment of adolescent peer drinking diminishes 
the protective effect of an ADH1B variant in chapter 2, we would hypothesize that the social 
context of low parental monitoring would likewise decrease the protective effect of metabolizing 
variants on early adolescent drinking behaviors. Similar hypothesis-driven studies of robust 
genetic factors may add to our knowledge of the complex role of these genes on the development 
of substance use behaviors.  
Future studies may also seek to expand on these findings with individual genes to build 
composite risk scores that predict the development of substance use disorders based on several 
genetic and environmental factors. Accurate prediction tools could inform intervention strategies 
that aim to identify at-risk individuals and prevent disease progression.  
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Translation to long-term disease risk and tailored therapies  
 In this dissertation, I identified and refined associations between robust genes and 
substance use disorders. An important next step is to extend these findings to long-term disease 
risk as well as response to treatments. Excessive alcohol use and persistent tobacco smoking are 
both associated with increased risk of a variety of chronic diseases, and it is important to 
understand how observed genetic associations with substance use disorders translate to related 
disease risk and response to treatments. For example, previous studies show that rs16969968 is 
the strongest genetic risk factor for lung cancer and chronic obstructive pulmonary disease 
(Amos et al., 2008, Hung et al., 2008, Pillai et al., 2009, Thorgeirsson et al., 2008) as well as 
influences response to different smoking cessation therapies (Chen et al., 2012). An important 
next step is to test whether these low frequency and rare CHRNA5 coding variants similarly 
increase the risk of smoking-related diseases and response to cessation treatment. This 
knowledge could inform personalized medical care of individuals who suffer from substance use 
disorders. 
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